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INTEGRATION OF MULTI-PLATFORM HIGH-DIMENSIONAL
OMIC DATA
by
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Advisory Professor: Kim-Anh Do, Ph.D.
The development of high-throughput biotechnologies have made data accessible
from di↵erent platforms, including RNA sequencing, copy number variation, DNA
methylation, protein lysate arrays, etc. The high-dimensional omic data derived
from di↵erent technological platforms have been extensively used to facilitate com-
prehensive understanding of disease mechanisms and to determine personalized health
treatments. Although vital to the progress of clinical research, the high dimensional
multi-platform data impose new challenges for data analysis. Numerous studies have
been proposed to integrate multi-platform omic data; however, few have e ciently
and simultaneously addressed the problems that arise from high dimensionality and
complex correlations.
In my dissertation, I propose a statistical framework of shared informative fac-
tor model (SIFORM) that can jointly analyze multi-platform omic data and explore
their associations with a disease phenotype. The common disease- associated sample
characteristics across di↵erent data types can be captured through the shared struc-
ture space, while the corresponding weights of genetic variables directly index the
strengths of their association with the phenotype. I compare the performance of the
proposed method with several popular regularized regression methods and canoni-
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cal correlation analysis (CCA)-based methods through extensive simulation studies
and two lung adenocarcinoma applications. The two lung adenocarcinoma appli-
cations jointly explore the associations of mRNA expression and protein expression
with smoking status and survival using The Cancer Genome Atlas (TCGA) datasets.
The simulation studies demonstrate the superior performance of SIFORM in terms of
biomarker detection accuracy. In lung cancer applications, SIFORM identifies many
biomarkers that belong to key pathways for lung tumorigenesis. It also discovers
potential prognostic biomarkers for lung cancer patients survival and some biomark-
ers that reveal di↵erent tumorigenesis mechanisms between light smokers and heavy
smokers.
To improve the prediction accuracy and interpretability of the proposed model,
I extend it to PSIFORM by incorporating existing biological pathway information
to current statistical framework. I adopt a network-based regularization to ensure
that the neighboring genes in the same pathway tend to be selected (or eliminated)
simultaneously. Through simulation studies and a TCGA kidney cancer application,
I show that PSIFORM outperforms its competitors in both variable selection and
prediction. The statistical framework of PSIFORM also has a great potential in
incorporating the hierarchical order across the multi-platform omic measurements.
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1. Introduction and Background
In this chapter, I review several methods commonly used for integrative omic data
analysis and biological pathway knowledge incorporation.
1.1 Introduction
The success of the Human Genome Project allows for genome-wide studies of vari-
ous biological activities in humans and other organisms. The extensive development of
high-throughput biotechnologies have made data accessible from di↵erent platforms,
including RNA sequencing, copy number variation, DNA methylation, and protein
lysate arrays. These high-dimensional omic data derived from di↵erent technological
platforms have been extensively used to facilitate comprehensive understanding of
disease mechanisms (e.g., the genetic profiles that are associated with tumor patho-
genesis, progression, and prognosis) and to determine personalized health treatments,
especially for cancer patients [1, 2].
Although vital to the progress of biomedical research, these multi-platform data
impose new challenges for data analysis. In addition to high dimensionality and
complex correlations within and across platforms, di↵erent types of omic data likely
have di↵erent scales and distributions [3]. It is also recognized that the incorpora-
tion of existing biological information (e.g., biological pathways) into the analysis of
multi-platform omic data can lead to more accurate prediction and improved inter-
pretability of the results [4, 5]. Therefore, e↵ective analytical methods are desirable
to extract and integrate useful information from the emerging data platforms with
proper utilization of the existing biological knowledge.
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Numerous integrative analyses of multi-platform data have been proposed to study
the interplay within and between di↵erent levels of biological data[6, 7, 8]. Some of the
analyses mainly depend on biological knowledge and experimental results[9, 10, 11],
while others are more statistical methodology [12, 13, 14]. This dissertation focuses on
the latter. A large number of statistical methods have been discussed for di↵erent ap-
plications and purposes. For example, pairwise correlation of genetic variables (e.g.,
weighted gene correlation network analysis[15]) is used to infer molecular network
interactions. Network analysis (e.g., di↵erential network analysis in genomics[16])
identifies active or aberrant subsets in a certain biological system by using molecular
network interactions based on graphical models. Bayesian network approaches[17, 18]
identify biomarkers that are associated with clinical outcomes by incorporating an-
other type of biomarkers collected from the same samples through prior distribu-
tions. Penalized likelihood analysis (e.g., Lasso[19]) handles high-dimensional multi-
omic data by regularizing the coe cients. The commonly used regularized regression
methods are briefly discussed in Section 1.2. Canonical correlation analysis (CCA)
determines the linear relationship between two sets of biological variables on the same
set of samples. This line of work includes sparse CCA, supervised CCA, and multiple
CCA [35, 36, 39], which are briefly introduced in Section 1.3. However, few of these
methods have e ciently and simultaneously addressed the problems that arise from
high dimensionality and complex correlations. In this dissertation, I propose a regu-
larized regression-based framework of the shared informative factor model (SIFORM)
to detect predictive biomarkers from high-throughput multi-platform data for a re-
sponse variable of interest, which is typically a disease-associated phenotype.
Methods for the incorporation of biological knowledge have also been discussed
in the statistical literature [4, 5, 20, 21, 22, 23, 24, 25]. This dissertation focuses
on incorporating existing pathway information into statistical models. Biologically
related genes are known to form groups called pathways. The genes on the same
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pathway have similar functions and may be associated with a disease phenotype in
a similar manner. In addition, the genes within and between pathways interact with
each other in di↵erent ways [20]. Many databases have been developed to store
the existing biological pathway knowledge attained from biomedical research. Some
examples include protein-protein interaction (PPI) networks that are available from
the Biomolecular Interaction Network Database (BIND) [26], and biological pathways
in the Kyoto Encyclopedia of Genes and Genomes (KEGG) [27]. Hence, it is both
desirable and feasible to incorporate pathway information to improve the prediction
accuracy and interpretability of statistical methods.
Most of the pathway incorporation methods use graphical models to characterize
the network structure of genetic variables. A gene-gene network can be represented
as a weighted graph G = (V,E,W ), where V is the set of vertices that correspond to
the p genetic variables, E = {u ⇠ v} is the set of edges indicating that the variables u
and v are linked within the network through edge e = (u ⇠ v), and W is the weights
of the edges. In W, !(u, v) denotes the weight of edge e = (u ⇠ v), which represents
the probability that vertices u and v are connected [21]. In applications, !(u, v) is
chosen as
p
dj or simply 1, where dj is the degree of node j, that is, the number of
edges connected to j [21, 23]. The idea of weighted graphs is demonstrated in Figure
1.1(a).
Current graphical model-based statistical methods for incorporating pathway in-
formation mainly include Bayesian models [4, 20, 24, 25] and penalized regression
approaches [5, 21, 22, 23]. In Bayesian settings, some researchers use a Markov ran-
dom field prior that captures the gene-gene interaction network to select genetic vari-
ables correlated with outcomes [24, 25]. Others combine penalized regression methods
with Bayesian approaches. For example, Rockova proposed a Bayesian Lasso method
by using pathway information to pose within-group sparsity rather than as a source
of strict regularization constraints [20]. The penalized regression models post con-
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straints on the coe cients by making assumptions about the similarity of genes in
the same pathway, as Figure 1.1(b) shows. This line of work is discussed in Section
1.4 in detail. In this dissertation, a novel penalized regression approach is proposed
to incorporate prior pathway knowledge into the shared informative factor model.
Figure 1.1.: Graph-based biological pathway structure
4
1.2 Regularized regression methods
In this section, I present a brief review of commonly used variable selection meth-
ods, including the L1-penalty-based Lasso [19], its improved version, adaptive Lasso
(adaLasso) [28], a combination of L1 and L2, the elastic net [31], and smoothly clipped
absolute deviation (SCAD) [32, 33].
Suppose that we have n samples, each of which has p predictor variables and
one response variable. This can be expressed as (xi, yi), i = 1, 2, · · · , n, where xi=
(xi1, · · · , xip)T are the predictor variables and yi is the response. It is usually assumed
that the conditional mean of Y given X depends on the linear predictor  TX with
  =( 1, · · · ,  p)T . When p   n, conventional methods fail to handle the parameter
estimation robustly and e ciently due to the singularity of the design matrix. There-
fore, penalized likelihood methods are proposed to cope with the problems that arise
from high dimensionality. In the above settings, the generalized form of the objective
function is
l( ) 
pX
j=1
p (| j|), (1.1)
where l( ) is the log-likelihood function, and p (·) is a penalty function with tuning
parameter   [40].
The variable selection and regression coe cient estimation can be done simulta-
neously by maximizing the penalized likelihood function (1.1). When p (| |) =  | |q,
the regression is called penalized Lq-regression. This generalized form includes some
popular variable selection methods, such as penalized L1-regression (Lasso) and pe-
nalized L2-regression(ridge regression)[19, 30].
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1.2.1 Lasso
When q=1, the Lasso estimate is defined as follows
 ˆLasso = argmax
 
(
l( )   
pX
j=1
| j|
)
. (1.2)
There is no closed-form solution for Lasso because the solution is nonlinear in Y, but
there several algorithms have been proposed for maximizing the penalized likelihood
function numerically. Osborne et al. converted the maximization problem into a
quadratic programming problem and solved it in an iterative way [42]. Efron et al.
proposed the least angle regression (LARS) algorithm, which e ciently produces the
entire path of Lasso estimates for all values of   [43].
The tuning parameter   controls the amount of regularization. As   ! 0, we
obtain the least squares solutions; as   ! 1, all the coe cients are approximately
estimated as zeros. When   is su ciently but reasonably large, Lasso will cause some
of the coe cients to be exactly zero, leading to a sparse interpretable model with
excellent prediction accuracy. However, Lasso has limited capacity for selecting a
consistent model, and the selected model tends to give biased estimates for the large
coe cients and may have many false positives [19, 40, 41].
In 2001, Fan and Li proposed oracle properties as criteria for good penalty func-
tions. [32] The oracle properties include
1. Unbiasedness: The resulting estimator is nearly unbiased especially when the
true unknown parameter is large;
2. Sparsity: The resulting estimator automatically shrinks the su ciently small
estimated coe cients to zero to accomplish variable selection and to reduce model
complexity; and
3. Continuity: The resulting estimator is continuous in the data to reduce insta-
bility in model prediction.
6
Given the inconsistency and biasedness of Lasso, the oracle properties do not hold
[28, 32].
1.2.2 Adaptive Lasso
Adaptive Lasso (adaLasso), a weighted version of the Lasso, was proposed by
Zou, where the adaptive weights !j’s are adopted in the L1 regularized regression to
penalize di↵erent coe cients [28]. The adaLasso estimates are defined as
 ˆadaLasso = argmax
 
(
l( )   
pX
j=1
!j| j|
)
. (1.3)
The adaptive weight vector ! is usually chosen as | ˆ|  , where   > 0 and  ˆ is a
root-n consistent estimator of  0. Typically, ordinary least squares (OLS) estimates
are used when no collinearity is assumed, and L2 regression estimates are used when
correlation exists among predictors. Similar to Lasso, the adaLasso estimates can be
obtained by the LARS algorithm [28, 29, 43].
The adaLasso yields consistent estimates of the parameters while retaining the
attractive property of the Lasso. Furthermore, it has been shown to enjoy the oracle
properties [28].
However, adaLasso may not be able to deal with correlated predictors e ciently
for moderate sample sizes [29], and has one more parameter ( ) to tune compared to
Lasso.
1.2.3 Elastic Net
Zou and Hastie (2005) introduced the elastic net, a linear combination of L1 and
L2 penalties, as equation (1.4) shows [31].
 ˆEN = argmax
 
(
l( )  (1  ↵)
pX
j=1
| j|  ↵
pX
j=1
 2j
)
, (1.4)
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where the function (1   ↵)| | + ↵ 2 is called the elastic net penalty for ↵ 2 [0, 1).
When ↵=0, the elastic net becomes Lasso regression; when ↵=1, it reduces to simple
ridge regression [31].
Maximizing equation (1.4) is equivalent to a lasso-type optimization problem, so
elastic net estimates can also be obtained by LARS. Moreover, a LARS-based algo-
rithm called LARS-EN was proposed by Zou to solve the elastic net more e ciently
[31]. The L2 penalty in the elastic net encourages the simultaneous selection or elim-
ination of strongly correlated variables for the model, which is called a ”grouping
e↵ect”. However, the elastic net does not reveal the underlying group structure in its
solution and does not possess oracle properties [44].
1.2.4 Smoothly Clipped Absolute Deviation (SCAD)
In Lq-regression, the penalty with q = 1 does not satisfy the condition of unbiased-
ness; the penalty with q > 1 does not satisfy the sparsity condition; and the penalty
with 0  q < 1 does not satisfy the continuity condition. For these reasons, Fan and
Li (2001) introduced the smoothly clipped absolute deviation (SCAD), which has the
following form[40]:
 ˆSCAD = argmax
 
(
l( ) 
pX
j=1
[ 2   (| j|   )2I(| j| <  )]
)
. (1.5)
The SCAD penalty is P (| |) =  2 (| |  )2I(| | <  ), and its first-order derivative
is P 0 (| |) =  I(| |   ) + (a  | |)+a 1 I(| | >  ), where a is suggested to be 3.7. The
SCAD penalty satisfies the aforementioned oracle properties [32].
Since the SCAD penalty is nonconcave and nondi↵erentiable, it cannot be solved
by convex optimization. Several algorithms are proposed to optimize nonconcave
penalized likelihood functions, including local quadratic approximation (LQA) and
local linear approximation (LLA)[32, 45].
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The LQA algorithm proposed by Fan and Li [32] locally approximates the objec-
tive function by a quadratic function. Given an initial value  (k), the penalty function
P (| |) can be locally approximated by a quadratic function, as shown by (1.6).
P (| |) ⇡ P (| (k)|) + 1
2
P 0 (| (k)|)
| (k)| [ 
2    (k)2]. (1.6)
With this approximation, maximizing the penalized likelihood can be converted to a
least squares problem with a closed-form solution. However, none of the elements of
 (k) shrink exactly to zero. Instead, the very small coe cients need to be set to 0
manually [32, 40, 45].
To solve this problem, Zou and Li [45] proposed a better approximation, LLA,
which can be represented in the following form:
P (| |) ⇡ P (| (k)|) + P 0 (| (k)|)(| |  | (k)|). (1.7)
The LLA estimators at each iteration naturally adopt a sparse representation. There-
fore, Zou and Li advocate the one-step LLA estimator for the final estimates. The
one-step estimator has been proven to be e cient as the fully iterative estimator and
enjoys the oracle properties, provided that the initial values and tuning parameters
are appropriately chosen. Furthermore, it can dramatically reduce the computational
cost [45].
The commonly used penalized regression methods satisfactorily handle the p  n
problem. However, these variable selection approaches simply aggregate genetic vari-
ables derived from di↵erent platforms as covariates in regression models. By doing so,
these methods lack the ability to consider the discrepancy in di↵erent platforms. They
also fail to detect the correlation structure among the variables [12, 46].To address
these problems, I apply the regularization method to the proposed shared informative
factor model to integrate multi-platform data and select the genetic variables that
9
are associated with disease phenotype simultaneously. Specifically, SCAD is adopted
for its good theoretical properties and promising empirical results.
1.3 Canonical correlation analysis (CCA)-based methods
This section consists of a brief review of several commonly used CCA-based meth-
ods: sparse CCA, supervised CCA (sCCA), multiple CCA (mCCA), and collaborative
regression (CollRe) [34, 35, 36, 39].
Assuming n samples have two standardized datasets X1 and X2 of dimensions
n ⇥ p1 and n ⇥ p2, CCA seeks the linear combinations (or canonical variates) of the
variables in X1 and the variables in X2 that are maximally correlated with each
other. This problem is equivalent to determining !1 and !2 by maximizing the CCA
criterion [35]
max
!1,!2
!T1X
T
1 X2!2 subject to !
T
1X
T
1X1!1 = !
T
2X
T
2X2!2 = 1, (1.8)
where !1 2 Rp1 and !2 2 Rp2 are canonical vectors (or weights). The optimal
canonical vectors identify the genetic variables in X1 and X2 that maximize the
correlation between linear combinations X1!1 and X2!2. There are closed-form
solutions for optimal canonical vectors !1 and !2.
CCA limits the probability of committing type I errors because it allows for si-
multaneous comparisons among the variables, which avoids inflated p-values from
multiple testing [37]. However, CCA may fail when the relationship between the
canonical variates is nonlinear. In addition, since this method is based on the corre-
lation coe cient, it is very sensitive to outliers [38].
1.3.1 Sparse CCA
In genetic studies, the number of features of genomic data usually greatly exceeds
the number of samples. CCA cannot be directly applied to solve this high-dimensional
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problem. Therefore, sparse CCA has been proposed [35, 36]. In sparse CCA, penalty
functions P1, 1(·) and P2, 2(·) are incorporated to determine the sparse canonical
vectors !1 and !2 by maximizing the sparse CCA criterion:
max
!1,!2
!T1X
T
1 X2!2 subject to ||!1||2 6 1, ||!2||2 6 1, P1, 1(!1) 6 c1, P2, 2(!2) 6 c2.
(1.9)
Typically, convex penalty functions P1, 1(·) and P2, 2(·) (e.g., Lasso, fused Lasso) are
used to render (1.9) to a convex problem. The convex problem can be solved by an
iterative algorithm, which maximizes the objective function (1.9) by fixing !1 and
!2 alternately in each step. The tuning parameters  1 and  2 are determined by a
permutation-based algorithm [35].
1.3.2 Sparse multiple CCA (mCCA)
The availability of multi-platform biological data makes it necessary to investigate
the association among multiple datasets. Sparse CCA can be easily extended to sparse
multiple CCA (mCCA) to accommodate the complex relationship among multiple
datasets.
Suppose we have n samples with K standardized data sets denoted byX1, · · · ,XK
with pivariables in each dataset. Similar to (1.9), sparse mCCA can be demonstrated
by [35]:
max
!1,···!K
X
i<j
!Ti X
T
i Xj!j subject to ||!i||2 6 1, Pi(!i) 6 Ci, 8i, (1.10)
where !i 2 Rpi and Pi’s are convex penalty functions. The optimal canonical vectors
!i can be obtained by a similar iterative procedure. In each iteration step, !i is
obtained by fixing !js for all j 6= i. The algorithm repeats until a convergence
criterion is reached [35].
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1.3.3 Sparse supervised CCA (sCCA)
The above methods focus only on the association among genetic variables, with-
out making use of the disease phenotype or clinical outcome (e.g., smoking status,
survival). Sparse supervised CCA (sCCA) is thus proposed to study the association
of genetic variables with the clinical outcome.
Suppose that a quantitative clinical outcome y 2 Rn is available in addition to
genetic matrices X i’s, then sparse sCCA is defined to seek the linear combination of
the variables in X i’s that are highly correlated with each other and associated with
the outcome y as follows:
max
!1,··· ,!K
X
i<j
!Ti X
T
i Xj!j subject to ||!i||2 6 1, Pi(!i) 6 Ci,!il = 0 8l /2 Qi, (1.11)
whereQi is the set of features inX i that are correlated with y. The optimal canonical
vectors of sparse sCCA can be obtained by a similar iterative algorithm, as described
in previous sections.
1.3.4 Collaborative regression (CollRe)
A novel form of supervised CCA, collaborative regression (CollRe), is proposed
to study the relationship between the response variable and genetic variables from
di↵erent assays [39].
It is assumed that we have n samples, each of which has two genetic matrices X
and Z of dimensions n⇥ px and n⇥ pz and a response vector y. The coe cients ✓x
and ✓z, which contain the weights of the features for the outcome, can be obtained
by minimizing the objective function [39]:
J(✓x,✓z) =
bxy
2
||y  X✓x||2 + bzy
2
||y  Z✓z||2 + bxz
2
||X✓x  Z✓z||2, (1.12)
where bxy, byz,and bxz are parameters that control the relative importance of the three
terms in the objective. For simplicity, bxy, byz,and bxz can be set as 1. The key idea
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of CollRe is to force the two genetic matrices X and Z to make similar contributions
to prediction by penalizing ||X✓x   Z✓z||, the di↵erence between the fitted linear
predictors ||y  X✓x|| and ||y  Z✓z||.
It is also easy to extend CollRe to account for sparse genetic matrices by defining
a penalized version of CollRe (pCollRe). The pCollRe coe cients can be obtained by
minimizing the following objective [39]:
F (✓x,✓z) =
bxy
2
||y X✓x||2+ bzy
2
||y Z✓z||2+ bxz
2
||X✓x Z✓z||2+P x 1(✓x)+P z 2(✓z),
(1.13)
where P x 1(✓x) and P
z
 2(✓z) are convex penalty functions (e.g., Lasso, ridge, and fused
Lasso). pCollRe is more e cient than sparse CCA, since the tuning parameters  1 and
 2 can be determined by the e cient LARS algorithm rather than the permutation-
based algorithm. However, this method is not well suited for prediction [39].
CCA provides an e cient way of performing an integrative analysis for high-
dimensional genetic variables from two platforms. The extensions of CCA allow for
the integration of more than two data sets and the incorporation of an outcome into
the analysis. However, the series of CCA-based methods have the inherent drawback
of not being able to capture the nonlinear relationships between canonical variates.
1.4 Statistical methods for biological knowledge incorporation
A penalized regression-based method is used for incorporating known pathway
information due to its easy application to SIFORM. In this section, I review the fol-
lowing specific penalized regression-based methods that incorporate pathway infor-
mation: the graph constrained estimation (Grace) method [21], an adaptive version
of graph constrained estimation (aGrace) [22], a generalized class of the network-
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constrained penalty proposed by Pan et al. (grouped L -norm penalty) [5], and a less
stringent version of Pan’s proposed penalty function (TTLPI and LTLPI) [23].
1.4.1 Graph constrained estimation (Grace)
Recall the graphical models introduced in Section 1.1. In the graphical model,
genetic variables are indicated by a set of vertices, and two directly connected vertices
are represented as j ⇠ j0. The graph constrained estimation (Grace) method proposed
by Li and Li (2008) assumes that the genes connected within a subnetwork have
similar functions and therefore smoothed regression coe cients. This idea can be
illustrated by a penalty function with two terms, as equation (1.14) illustrates. The
first term is a L1-penalty for variable selection, and the second term is used to smooth
the weighted coe cients over the network [21].
PGrace 1, 2 ( ) =  1
pX
j=1
| j|+  2
X
j⇠j0
(
 jp
dj
   j0p
dj0
)2, (1.14)
where dj is the degree (the number of edges) of node j. The degrees scale the coe -
cients to allow the highly connected genes, the hub genes, to have larger coe cients
so that small changes in the expressions of such genes can lead to large changes in
the response [21].
Maximizing the penalized regression with penalty function (1.14) is equivalent
to solving a Lasso-type optimization problem and thus enjoys the computational
advantage of Lasso [21].
1.4.2 Adaptive graph constrained estimation (aGrace)
In some applications, two connected genes might be negatively correlated with the
phenotypes and therefore have opposite signs in their regression coe cients. How-
ever, the above Grace method fails to smooth the genes that are linked within the
subnetwork and which have di↵erent regression coe cients signs. To account for the
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sign di↵erences, Li and Li (2010) [22] proposed an adaptive version of Grace method
(aGrace). In this method, | j|/
p
dj = | j0 |/
p
dj0 for j ⇠ j0 is encouraged in the
penalty function, as equation (1.15) shows.
P aGrace 1, 2 ( ) =  1
pX
j=1
| j|+  2
X
j⇠j0
(
sign( ˜j) jp
dj
  sign( ˜j0) j0p
dj0
)2, (1.15)
where  ˜j is an initial estimate. Typically, the OLS estimate is employed for p < n,
and the elastic net estimate is employed for p > n. The main idea is to use sign( ˜j)
to estimate sign( j), which, however, may not work well for high-dimensional data:
since we do not even know which  j’s are 0 for variable selection, it is more di cult
to estimate their signs [22, 23].
The coordinate descent algorithm is used to optimize the penalized likelihood
function that uses (1.15) as a penalty function [47].
1.4.3 Grouped L -norm penalty
In addition to the incapability of capturing the connected genes with opposite re-
gression coe cient signs, the Grace approach also fails to accomplish grouped variable
selection. To address this problem, Pan et al. (2010) [5] proposed a grouped L -norm
penalty to automatically realize grouped variable selection and exploit grouping ef-
fects. Given a pre-specified   > 1, this class of penalties can be illustrated by equation
(1.10):
P , ( ) =  
X
j⇠j0
[(
| j|
!j
)  + (
| j0 |
!j0
) ]
1
  , (1.16)
where !j is a user-specified weight to realize di↵erent types of shrinkages. Usually,
three choices are considered for !j: (i) !j = d
 +1
2
j ; (ii)!j = dj; (iii) !j = d
 
j , which
lead to three di↵erent types of smoothness on the parameters [5].
Pan et al. proposed a slightly modified generalized boosted Lasso (GBL) algo-
rithm to maximize the penalized likelihood function [48]. The GBL algorithm yields
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an approximate solution path  ( ˆ) through a coordinate-wise search and repeated
calculations of the objective function. Among the set of  ’s at a finite number of
tuning parameter values, the final coe cient estimates   (k0) are obtained at tuning
parameter  (k0), which minimizes the prediction mean squared error [5].
The empirical results of this method demonstrate better performance in variable
selection than that of Grace, but its parameter estimates may be severely biased [23].
1.4.4 Truncated lasso penalty (TLP)-based penalty
All the above methods assume the smoothness of weighted   or | | over the
network. This assumption may be too stringent in some applications, because the
genes connected within the same subnetwork may be correlated with the outcome
with di↵erent e↵ect sizes. Hence, Kim et al. proposed a new network-based penalty
without the assumption of smoothness on regression coe cients. Instead, the pro-
posed penalty only assumes that two connected genes are more likely to participate
(or not participate) together in the same biological process than two distant genes,
as equation (1.17) shows [23].
P ( ) =  1
pX
j=1
I(| j| 6= 0) +  2
X
j⇠j0
|I( | j|
!j
6= 0)  I( | j0 |
!j0
6= 0)|, (1.17)
where the first penalty term is for variable selection and the second one encourages
the simultaneous selection (or elimination) of connected nodes in a subnetwork. Since
the indicator function I(·) is not continuous, Kim et al. adopted a truncated Lasso
penalty (TLP), J⌧ (|z|) = min( |z|⌧ , 1), which approximates I(|z| 6= 0) as ⌧ ! 0+.
The tuning parameter ⌧ determines the degree of approximation [23, 49]. The TLP
is applied to (1.17) as a computational surrogate of I(|z| 6= 0) and therefore leads
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to the following penalty function TTLPI , with a TLP for variable selection and a
TLP-based penalty for grouping the genetic variables [23]:
P TTLP⌧, 1, 2( ) =  1
pX
j=1
J⌧ (| j|) +  2
X
j⇠j0
|J⌧ ( | j|
!j
)  J⌧ ( | j0 |
!j0
)|. (1.18)
For computational e ciency, Kim et al. proposed another penalty function LTLPI
(1.19), which uses Lasso rather than TLP for variable selection [23]:
PLTLP⌧, 1, 2( ) =  1
pX
j=1
| j|+  2
X
j⇠j0
|J⌧ ( | j|
!j
)  J⌧ ( | j0 |
!j0
)|. (1.19)
Since the TLP function is non-convex, di↵erence convex (DC) programming is used to
decompose the non-convex function into a di↵erence of two convex functions, which
then can be solved by convex optimization [23, 50].
The existing pathway knowledge can be structured by the network-based penalty
functions introduced in Section 1.4 and then can be easily applied to the framework
of SIFORM. Specifically, I adopt the idea of TLP for its flexibility and its better
approximation to reality. I propose a penalty function that uses SCAD for variable
selection and TLP for simultaneous selection of connected variables. The proposed
penalty with its computation issues and theoretical properties is discussed in Chapter
3.
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2. Shared Informative Factor Models for Integration of
Multi-platform Bioinformatic Data (SIFORM)
In this chapter, I propose a statistical framework of shared informative factor models
(SIFORM) to integrate multi-platform omic data and explore their association with
a disease phenotype. The common disease-associated sample characteristics across
di↵erent data types can be captured through the shared structure space, while the
corresponding weights of genetic variables directly index the strengths of their asso-
ciation with the phenotype.
Extensive simulation studies demonstrate the superior performance of SIFORM in
terms of biomarker detection accuracy compared to the performance of several popular
regularized regression methods and CCA-based methods. I also applied SIFORM to
two lung adenocarcinoma datasets from The Cancer Genome Atlas (TCGA) database
to jointly explore the associations of mRNA expression and protein expression with
smoking status and survival rate. Both studies identified many biomarkers that be-
long to key pathways for lung tumorigenesis, some of which are known to show di↵er-
ential expression across smoking levels or between long-term survivors and short-term
survivors. SIFORM also discovered potential biomarkers that reveal di↵erent mecha-
nisms of lung tumorigenesis between light smokers and heavy smokers and prognostic
biomarkers for survival.
2.1 Motivation
High-dimensional omic data derived from di↵erent platforms have been exten-
sively used to facilitate comprehensive understanding of disease mechanisms [1, 2].
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Numerous studies have integrated multi-platform omic data [6, 7, 8, 9, 10, 11, 12, 13,
14, 15, 16, 17, 18, 19]; however, few have e ciently and simultaneously addressed the
problems that arise from high dimensionality and complex correlations.
For instance, the penalized regression-based variable selection methods introduced
in Section 1.2 [19, 28, 31, 32] satisfactorily address the extremely high dimensionality
of the covariate space, which is much larger than the number of samples. However,
these methods aggregate genetic variables from di↵erent platforms as covariates in
regression models without accounting for their correlation. The CCA-based meth-
ods introduced in Section 1.3 [35, 36, 39] e ciently integrate genetic variables from
multiple platforms but do not achieve satisfactory predictive performance and fail to
handle the nonlinear relationship among multi-platform data.
To address this problem, I propose a statistical framework, SIFORM, to integrate
multiple types of omic data, and investigate the association of the integrated data with
a disease-associated response variable. In contrast to the conventional factor models, I
incorporate the disease phenotype information into the factor space to detect genetic
variables that interact with the response variable. I also assume a common struc-
tured factor across multiple data types for the purpose of detecting di↵erent levels of
the important disease-associated genetic variables. The proposed framework lays a
foundation for incorporating existing biological knowledge into statistical models to
improve the biological relevance of results.
2.2 Methodology
2.2.1 A framework of shared informative factor models
In this section, I describe a new model framework to explore associations between
a disease phenotype and high-throughput genetic data generated from multiple (  2)
platforms. Herein, I focus on two-platform data for the purpose of demonstration.
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Let the n⇥ p1 matrix X1 and n⇥ p2 matrix X2 denote two data matrices containing
the intensity measurements of p1 genetic variables obtained from platform 1 and
those of p2 genetic variables obtained from platform 2, respectively. Correspondingly,
we let the length-n vector y denote the phenotypes of n subjects (e.g., smoking
status, cancer subtype). The system is built upon the generalized linear models,
considering exponential family of distributions for genetic variables in X1 and X2
(e.g., continous measurements, count data). The transformed mean functions of the
expression intensities of genetic variables can be expressed via canonical link functions
g1 and g2, respectively corresponding to X1 and X2, as follows,
g1 {E(X1)} = ↵1 +CA,
g2 {E(X2)} = ↵2 +CB. (2.1)
For the demonstration, I focus on continuously measured genetic variables (e.g., gene
expression, protein expression, DNA copy number), for which the identity link g1(µ) =
g2(µ) = µ is used. I also assume the genetic variables in X1 and X2 follow normal
distributions (posterior to transformation when appropriate). The n ⇥ 1 parameter
vectors ↵1 and ↵2 respectively correspond to baseline sample e↵ects in two sets
of genetic data. The jth columns of the n ⇥ p1 residual matrix "1 of X1 and the
n⇥p2 residual matrix "2 ofX2 follow mean-0 normal distributions with the respective
variances  21j and  
2
2j. Our interest is drawn to the multiplicative terms CA and CB,
which capture the associations between the phenotype and genetic variables. The
proposed framework has two main distinctions from the conventional factor models
that have similar forms. First, the n⇥ 1 parameter vector C is structured to deliver
the phenotype information. In the case of a K-categorical phenotype (e.g., K levels
of smoking status), C = {c1, ..., c1, ...., cl, ..., cl, ..., cK , ..., cK}T , with cl indicating the
common e↵ect that the subjects in the lth phenotype contribute to the associations
between the phenotypes and genetic variables. Second, the same C is employed in
these two models to represent the common intrinsic sample characteristics in the two
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sets of genetic data. The length-p1 vector A and length-p2 vector B contain the
weights that the genetic variables contribute to the structured sample characteristics
shared by the two sets of genetic data. The elements ofA andB are called association
scores. This new system is called shared informative factor models (SIFORM). For
model identifiability, the constraint
Pn
i=1 c
2
i = 1 is imposed on C. I also follow the
established practice of standardizing the intensity values of each genetic variable prior
to the downstream analysis.
2.2.2 Parameter Estimation
In the above-described framework, the log-likelihood of the two sets of observed
genetic data is
l =
p1X
j=1
nX
i=1
⇢
 (x1ij   ↵1i   cl · aj)
2
2 21j
  1
2
log(2⇡ 21j)
 
+
p2X
j=1
nX
i=1
⇢
 (x2ij   ↵2i   cl · bj)
2
2 22j
  1
2
log(2⇡ 22j)
 
. (2.2)
To identify important genetic variables associated with the phenotype of interest,
I also impose a sparsity regularization on the elements of the parameter vectors A
and B in model estimation. I adopt the SCAD penalization method [32], which
uses symmetric penalty functions that are non-concave on (0,1) to simultaneously
select the variables and estimate the coe cients. SCAD has been shown to have good
theoretical properties and to o↵er promising empirical results.
The parameter estimates are obtained via minimizing the following objective func-
tion, which is simply the negative penalized log-likelihood
S =  l +
p1X
j=1
P 1(|aj|) +
p2X
j=1
P 2(|bj|), (2.3)
where P (.) =  2   (.    )2I(. <  ), and its first-order derivative is P 0 (.) =  I(. 6
 ) + (a  .)+a 1 I(. >  ). I take the value of a = 3.7 as suggested by [32]. Herein,  1 and
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 2 are the penalty tuning parameters that respectively correspond to the two sets of
genetic data.
I adopt the local linear approximation of [45] for the sparsity penalty term and find
a convex function to implement the e cient majorization-minimization (MM) algo-
rithm [51]. The MM algorithm, which stands for the minorize-maximize or majorize-
minimize algorithm, is a class of algorithms for finding a maximizer or minimizer of
non-di↵erentiable penalty functions in an iterative way. Specifically, the minimization
problem consists of two steps at the kth iteration: majorization and minimization. In
the majorization step, a di↵erentiable function g(✓|✓(k)) is created as a surrogate for
the non-di↵erentiable objective function f(✓). The function g(✓|✓(k)) > f(✓) is said to
majorize function f(✓) at ✓(k), and has the following properties. In the minimization
step, the di↵erentiable majorization function g(✓|✓(k)) is minimized rather than the
actual objective function f(✓). If ✓(k+1)) denotes the minimizer of g(✓|✓(k)), then it
can be shown that f(✓(k+1)) > f(✓(k)). This is called the descent property of the MM
algorithm, which guarantees the numerical stability of the algorithm [51].
Using P 1(|aj|) as an example, the local linear approximation can be expressed as
P 1(|aj|) ⇡ P 1(|a(k)j |) + P 0 1(|a(k)j |)(|aj|  |a(k)j |), (2.4)
where a(k)j is the value of aj estimated at step k. Then the majorization function of
the local linear approximated penalty is
G 1(|aj|) = P 0 1(|a(k)j |)
a2j + a
(k)2
j
2|a(k)j |
+ P 1(|a(k)j |)  P 0 1(|a(k)j |)(|a(k)j |). (2.5)
The majorization function G 2(|bj|) for P 2(|bj|) can be obtained in similar way.
Thus, the parameter estimates are obtained by iteratively minimizing the following
objective function,
S⇤ =  l +
p1X
j=1
G 1(|aj|) +
p2X
j=1
G 2(|bj|).
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At the (k + 1)th step, the closed-form penalized log-likelihood estimators for the
elements of A and B can be obtained as
aˆj
(k+1) =
|a(k)j |
Pn
i=1 ci(x1ij   ↵1i)
|a(k)j |+  21jP 0 1(|a(k)j |)
(2.6)
and
bˆj
(k+1)
=
|b(k)j |
Pn
i=1 ci(x2ij   ↵2i)
|b(k)j |+  22jP 0 2(|b(k)j |)
. (2.7)
The closed-form solutions of all the other parameter estimates are obtained via
taking the partial derivative of log-likelihood function (2.2), as the following equations
show:
 ˆ21j =
Pn
i=1(x1ij   ↵ˆ1j   cˆi · aˆj)2
n
; (2.8)
 ˆ22j =
Pn
i=1(x2ij   ↵ˆ2j   cˆi · bˆj)2
n
; (2.9)
↵ˆ21i =
Pp1
j=1 x1ij   cˆi
Pp1
j=1 aˆj
p1
; (2.10)
↵ˆ22i =
Pp2
j=1 x2ij   cˆi
Pp2
j=1 bˆj
p2
; (2.11)
cˆl =
Pp1
j=1
Pnl
i=nl 1+1
aˆj
 ˆ21j
(x1ij   ↵ˆ1i) +
Pp2
j=1
Pnl
i=nl 1+1
bˆj
 ˆ22j
(x2ij   ↵ˆ2i)
(nl   nl 1)(
Pp1
j=1
aˆ2j
 ˆ21j
+
Pp2
j=1
bˆ2j
 ˆ22j
)
, (2.12)
where l = 1, · · ·K indicates the smoking status l.
Algorithm 1 demonstrates the details of the iterative parameter estimation proce-
dure. The convergence threshold " is set at 10 5. Extensive simulations show that the
estimation seems to stabilize within 300 iterations. Therefore, the iterative procedure
stops when either convergence is reached or 300 iterations are completed, whichever
occurs first.
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Algorithm 1 Iterative parameter estimation procedure
1. Input : X1, X2, y
2. Initialization :
2.1. ↵(0)1  0,↵(0)2  0
2.2.  (0)1j  var(X1(·j)),  (0)2j  var(X2(·j))
2.3. Assign 1,· · · ,K to ci according to the K-categorical phenotype y, then scale
C to have
Pn
i=1 c
2
i = 1. Use the scaled C as the initial value, C
(0).
2.4. Use least square estimators for A(0), B(0): a(0)j  
Pn
i=1 cix1ij, b
(0)
j  Pn
i=1 cix2ij
3. Do-while loop:
do{
Update 3.1-3.3 using closed-form estimators
3.1. ↵(k+1)1,2  (X1, X2,  2(k)1,2 , C(k), A(k), B(k))
3.2.  2(k+1)1,2  (X1, X2,↵(k+1)1,2 , C(k), A(k), B(k))
3.3. C(k+1)  (X1, X2,↵(k+1)1,2 ,  2(k+1)1,2 , A(k), B(k))
Update 3.4 using formula (2.6)
3.4. A(k+1)  (X1, C(k+1),↵(k+1)1 ,  2(k+1)1 )
Update 3.5 using formula (2.7)
3.5. B(k+1)  (X2, C(k+1),↵(k+1)2 ,  2(k+1)2 )
3.6. For each estimate, compute the di↵erence between current and previous
iteration steps:
 1 = |↵(k+1)1  ↵(k)1 |, 2 = |↵(k+1)2  ↵(k)2 |, 3 = | (k+1)1    (k)1 |, 4 = | (k+1)2  
 (k)2 |, 5 = |A(k+1)   A(k)|, 6 = |B(k+1)   B(k)|, 7 = |C(k+1)   C(k)|
} while( 1 > "|| 2 > "|| 3 > "|| 4 > "|| 5 > "|| 6 > "|| 7 > ")
4. Output :Aˆ A(k+1), Bˆ  B(k+1), Cˆ  C(k+1)
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2.2.3 Tuning Parameter Selection
The tuning parameters   = ( 1,  2) are important for calibrating the goodness-of-
fit for the data and model sparsity. I adopt the Bayesian information criterion (BIC)
[52], which is widely used in high-dimensional studies [53, 54], and defined as
BIC =  2l + log(n(p1 + p2)) · df( ),
where df( ) is proportional to the summation of the number of nonzeros in Aˆ and
the number of nonzeros in Bˆ.
The pair of ( 1,  2) that achieves the smallest BIC value is obtained by using a
two-dimensional grid search over a pre-determined space. A large value of   may lead
to an under-fitted model while a smaller   leads to an over-fitted model. I use the
range between 0 and 10 for each tuning parameter.
The BIC curve is expected to be convex over the tuning parameters. When the
BIC curve is convex, it is very easy to find its minimum. Sometimes the BIC curve
is L-shaped. When it is L-shaped, the point of maximum curvature is used as the
minimum, which is called the knee of the curve. To find the knee, I locate the point
on the curve that is furthest from a line fitted to the entire curve. This criterion
considers all data points on the curve at the same time.
2.3 Simulation
2.3.1 Data description
Extensive simulations are conducted to assess the performance of the proposed
SIFORM and compare its performance to those of three popular regularized regression
methods: SCAD, Lasso, adaptive Lasso (adaLasso) and CCA-based methods: mCCA
and pCollRe. These methods can be implemented directly using the respective R
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packages ncvreg, glmnet, parcor, and PMA. The tuning parameters are selected by
the 5-fold cross-validation procedure.
Seven simulation scenarios are used to study the various data generation models,
inter-genetic marker dependence structures, and residual variances. In scenarios 1-
3 and 5 - 6, the phenotype variable Y is categorized into four groups and two high-
dimensional genetic profiling matrices, X1 and X2. In the three penalized regression
methods, all the genetic variables in X1 and X2 are treated as the covariates to
predict the phenotype. Note that multinomial logistic regression models are used
for the response variable of smoking status in four categories. For SCAD, the union
of all the nonzero coe cients identified in three separate logistic regression models
is taken, treating the category of non-smoker as the reference group. In contrast,
SIFORM conveniently uses A and B to identify the important biomarkers despite
the di↵erent disease phenotypes. The performance of SIFORM is also investigated
when data come from three platforms in scenarios 4 and 7.
In brief, scenarios 1-4 generate genetic data X1 and X2 from model (2.1), and
scenarios 5-7 simulate discrete phenotype data from multinomial logistic regression
models. The matrices Xk(k = 1, 2, 3) in scenarios 5-7, and "k (k=1, 2, 3) in scenarios
1-4 are simulated from multivariate mean-0 normal distributions. The corresponding
variances are set to be 1 for all the multivariate normally-distributed variables in
scenarios 1-4. In scenario 6, they are sampled from a lung cancer data set obtained
from TCGA. In terms of the data dependence structure, the genetic variables in X1
and X2 are mutually independent in scenario 1; the genetic variables with nonzero
coe cients are correlated with ⇢ = 0.8, and 14%   32% of the remaining genetic
variables are weakly correlated with ⇢ = 0.2 in scenarios 2-5. Throughout all the
scenarios, sparse true biomarkers that are associated with the phenotype are assumed.
Additional details for the five simulation scenarios follow.
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• Scenario 1: I equally assign 120 samples to the four categories of the phenotype
y, which gives the corresponding C = (0.033, · · · , 0.033, 0.067, · · · , 0.067,
0.100, · · · , 0.100, 0.133, · · · , 0.133). Each sample has intensity measurements
collected over 100 genetic variables in data set 1 (X1) and over 100 genetic
variables in data set 2 (X2). In each data set, only the first 5 genetic variables
are associated with the phenotype, with the sparse coe cient vectors A1⇥100 =
(5, 7, 11, 15, 18, 0, · · · , 0) and B1⇥100 = (4, 8, 10, 14, 20, 0, · · · , 0). All the genetic
variables are assumed to be mutually independent. The baselines ↵1 and ↵2
are set at 0, and the intensity measurements in X1 and X2 are simulated from
model (2.1).
• Scenario 2: This scenario is the same as scenario 1, except that we assume a
blockwise compound symmetry correlation structure among the genetic vari-
ables to mimic real studies.
• Scenario 3: In this higher dimensional case, 160 samples are equally assigned
to four categories, and there are 1,000 variables in each of the two genetic data
sets. Among the genetic variables, only the first 50 have nonzero coe cients in
each data set. The data are generated in the same way as in scenario 2.
• Scenario 4: This scenario is the same as scenario 2, except that each sample has
100 additional genetic variables in data set 3 X3, with sparse coe cient vectors
M1⇥100 = (3, 6, 9, 12, 17, 0, · · · , 0).
• Scenario 5: I use a multinomial logistic regression model to generate the phe-
notype. I consider a total of 200 samples and 100 genetic variables, where
the first 5 variables are true biomarkers, in each of X1 and X2. Letting the
sparse coe cient vectors A(1)1⇥100 = (6, 14, 14, 24, 20, 0, · · · , 0), B(1)1⇥100 =
(4, 12, 10, 18, 18, 0, · · · , 0),A(2)1⇥100 = (3, 14, 11, 24, 24, 0, · · · , 0) andB(2)1⇥100 =
(2, 10, 13, 24, 23, 0, · · · , 0), A(3)1⇥100 = (2, 14, 15, 20, 25, 0, · · · , 0) and B(3)1⇥100
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= (2, 10, 11, 21, 23, 0, · · · , 0), we have the logit transformed predictor ⌘il =
log( P (Yi=l)P (Yi=4)) = A(l)X1i + B(l)X2i, l = 1, 2, 3. The probability of Yi = l is
pil = e⌘il/(1+
P3
k=1 e
⌘ik). Accordingly, I sample Yi from the multinomial dis-
tribution MN(1, pi1, pi2, pi3, pi4). The genetic intensity values follow multivari-
ate mean-0 normal distributions. The generated data are fairly balanced. For
example, a simulated data set contains 66, 40, 43, and 51 samples in the four
respective categories.
• Scenario 6: I investigate a higher dimensional setting for the data generated
under a multinomial logistic regression model, which is similar to scenario 4.
I consider 230 samples, with X1 and X2 respectively containing 3500 and 150
genetic variables. This dimensionality is comparable to that of the first TCGA
lung cancer data set I used to illustrate the real application of the proposed
method. Among the genetic variables, only the first 30 in X1 and the first 10
in X2 are the true predictors of the phenotype. As an example, a simulated
data set produces 59, 47, 49, and 75 samples in the four respective phenotype
categories.
• Scenario 7: I also investigate a 3-platform setting for the data generated un-
der a multinomial logistic regression model. In this scenario, the same X1,
X2, A(1,2,3)1⇥100 and B(1,2,3)1⇥100 are used as in scenario 5. The only di↵er-
ence is that each sample has 100 additional genetic variables in X3, with the
sparse coe cient vectors M(1)1⇥100 = (3, 9, 12, 15, 22, 0, · · · , 0), M(2)1⇥100 =
(4, 8, 12, 20, 23, 0, · · · , 0) and M(3)1⇥100 = (3, 10, 15, 19, 24, 0, · · · , 0). Yi is gen-
erated is the same way as described in scenario 5. As an example, a simulated
data set contains 29, 36, 47, and 88 samples in the four respective categories.
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2.3.2 Results
One hundred simulations are run for each scenario. I report the average value and
standard error of the true positive rate (TPR), true negative rate (TNR), and false
discovery rate (FDR) among the top genetic variables detected that have the largest
values of |A| or |B| for SIFORM, and the largest absolute values of the regression
coe cients for the other methods. For scenario 3 with 100 true biomarkers, I focus
on the top 10 biomarkers detected by di↵erent methods. For all the other scenarios,
I focus on the top 5 biomarkers detected.
I report the variable selection results in Table 2.1. The first four scenarios cor-
respond to the generation of data from the shared informative factor model (2.1),
considering independent and dependent genetic variables, di↵erent levels of dimen-
sionality, and di↵erent numbers of platforms. The simulations demonstrate the con-
sistently superior performance of the SIFORM method compared to those of the
other five methods in terms of biomarker detection accuracy across the scenarios.
The TPRs of SIFORM are strikingly higher than those of all the other methods in
each scenario, and SIFORM maintains the smallest FDRs and comparable TNRs
across all scenarios. Among the remaining methods, pCollRe generally has the best
performance under every criteria, especially in the high-dimensional scenario 3. This
is because both L1- and L2-norm penalties are used in pCollRe to smooth the esti-
mates [39]. mCCA has an overall large variance, and its performance seems easily
a↵ected by dimension. Among the penalized regression methods, SCAD detects the
highest number of true biomarkers while sacrificing false positives, and thus yields a
high FDR. The remaining two penalized regression approaches, Lasso and adaLasso,
detect fewer true biomarkers than the other two methods, and adaLasso produces a
lower FDR than Lasso and SCAD.
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Table 2.1: Comparison of TPRs, TNRs, and FDRs between SIFORM and five other
methods under seven simulation scenarios.
Scenario Method TPR TNR FDR
Scenario 1
SIFORM 0.983(0.038) 0.985(0.008) 0.000(0.000)
SCAD 0.676(0.129) 0.921(0.030) 0.342(0.319)
Lasso 0.466(0.133) 0.987(0.013) 0.170(0.159)
adaLasso 0.571(0.128) 0.991(0.011) 0.052(0.093)
pCollRe 0.677(0.104) 1.000(0.000) 0.014(0.051)
mCCA 0.603(0.243) 0.991(0.029) 0.048(0.090)
Scenario 2
SIFORM 0.989(0.031) 0.987(0.008) 0.000(0.000)
SCAD 0.266(0.178) 0.964(0.036) 0.350(0.320)
Lasso 0.323(0.094) 0.958(0.024) 0.436(0.178)
adaLasso 0.111(0.057) 0.995(0.001) 0.192(0.039)
pCollRe 0.540(0.091) 1.000(0.000) 0.068(0.099)
mCCA 0.688(0.277) 0.984(0.037) 0.022(0.142)
Scenario 3
SIFORM 0.959(0.015) 0.994(0.002) 0.000(0.000)
SCAD 0.195(0.036) 0.988(0.005) 0.441(0.222)
Lasso 0.093(0.020) 0.998(0.002) 0.136(0.121)
adaLasso 0.075(0.012) 0.999(0.001) 0.050(0.085)
pCollRe 0.542(0.031) 0.996(0.002) 0.001(0.010)
mCCA 0.068(0.014) 1.000(0.000) 0.000(0.000)
Scenario 4
SIFORM 0.950(0.090) 1.000(0.000) 0.000(0.000)
SCAD 0.364(0.102) 0.989(0.160) 0.335(0.299)
Lasso 0.287(0.112) 0.995(0.242) 0.212(0.144)
adaLasso 0.390(0.096) 1.000(0.147) 0.069(0.099)
pCollRe 0.430(0.072) 1.000(0.000) 0.086(0.115)
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mCCA 0.316(0.161) 0.999(0.005) 0.529(0.069)
Scenario 5
SIFORM 0.791(0.123) 0.987(0.007) 0.012(0.048)
SCAD 0.754(0.105) 0.925(0.024) 0.334(0.203)
Lasso 0.642(0.136) 0.903(0.028) 0.170(0.140)
adaLasso 0.675(0.130) 0.984(0.020) 0.016(0.055)
pCollRe 0.627(0.112) 0.994(0.000) 0.024(0.071)
mCCA 0.398(0.286) 0.970(0.045) 0.376(0.216)
Scenario 6
SIFORM 0.392(0.067) 0.999(0.005) 0.000(0.000)
SCAD 0.246(0.062) 0.988(0.004) 0.598(0.208)
Lasso 0.132(0.044) 0.990(0.003) 0.390(0.174)
adaLasso 0.106(0.033) 0.999(0.001) 0.110(0.140)
pCollRe 0.498(0.066) 0.996(0.001) 0.014(0.051)
mCCA 0.206(0.220) 0.973(0.044) 0.740(0.280)
Scenario 7
SIFORM 0.622(0.094) 1.000(0.000) 0.000(0.000)
SCAD 0.262(0.094) 0.967(0.014) 0.346(0.170)
Lasso 0.315(0.101) 0.929(0.019) 0.458(0.174)
adaLasso 0.413(0.090) 0.999(0.007) 0.056(0.095)
pCollRe 0.520(0.109) 1.000(0.000) 0.018(0.058)
mCCA 0.270(0.200) 0.966(0.043) 0.726(0.119)
I also consider generating data from logistic regression models under scenarios 5,
6, and 7, which represent di↵erent dimensionalities and numbers of platforms of ge-
netic data. While the di↵erences between SIFORM and the other three methods are
not as large as in the first three scenarios, the advantage of using SIFORM in terms
of selecting true biomarkers is still clear. In most scenarios, SIFORM detects the
most true biomarkers with the smallest FDR. In contrast, SCAD, Lasso, and mCCA
yield high FDR, implying that large numbers of trivial genetic variables are selected
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into the models. The results are still solid when genetic variables come from three
di↵erent platforms. pCollRe discovers more true positives than SIFORM in scenario
6. However, pCollRe may not be well-suited for prediction based on the evaluation
of the predictive performance of SIFORM and pCollRe by cross-validation [39]. For
simplicity, for each of the 100 data sets in scenario 6, I focus on n samples in the two
most extreme categories: y=1 and y=4. Specifically, leave-one-out cross-validation is
used. Among the n samples, n   1 are used as the training set to build a classifier,
which is then used to predict the phenotype of the remaining sample. This procedure
is repeated n times to obtain the overall misclassification rate for each data set. To
make a fair comparison, I focus on the predictive performance of the top 5 biomarkers
with the largest absolute estimated coe cient values as identified by each method.
The means (and standard deviations) of the misclassification rates of SIFORM and
pCollRe are respectively 0.283(0.085) and 0.409(0.090). These results indicate that
SIFORM significantly outperforms pCollRe in terms of prediction.
Figure 2.1 depicts the boxplots of the number of TPRs and FDRs obtained by all
six methods over 100 simulations under scenarios 3 and 7.
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Figure 2.1.: Comparison of number of TPRs and FDRs across 6 methods under
scenarios 3 and 7 (SIFORM)
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I also assess the performance of the BIC in the proposed framework. Using scenario
3 as an example, Figure 2.2 shows the BIC values along the tuning parameters  1 and
 2 in a simulated dataset. Reading from left to right in Figure 2.2, the subpanels
correspond to  1 values increasing from 2.5 to 4.6. In each subpanel, the BIC values
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are plotted against the values of  2 in increments of 0.3. The good behavior of the
BIC method is indicated by clear convex curves, with ( 1 = 3.4,  2 = 4) chosen as
the optimal tuning parameter values for this dataset. In a common scenario, it can
be told that the results are very similar across di↵erent simulated datasets, and thus,
I use the tuning parameter values obtained from a single dataset for computational
consideration.
Figure 2.2.: BIC curve in two-dimensional grid search under scenario 3
2.4 Lung adenocarcinoma applications
Lung cancer is the leading cause of cancer deaths in the United States [55]. Among
the major histological types of lung cancer, adenocarcinoma is the most common form
in non-smokers [56]. I investigate the applicability of SIFORM to the TCGA lung
adenocarcinoma data set available through the data portal hosted by the National
Cancer Institute (http://cancergenome.nih.gov/). In particular, two disease pheno-
types, smoking status and survival, are studied to demonstrate the application of
34
SIFORM and explore new molecular biomarkers that may facilitate the comprehen-
sive understanding of lung cancer.
2.4.1 The association of biomarkers with smoking status
Cigarette smoking is the most important risk factor for lung cancer; however,
approximately 25% of lung cancer cases are not attributable to tobacco use. Striking
di↵erences in the epidemiological, clinical and molecular characteristics of lung cancer
have been demonstrated when the cancer arises in a non-smoker versus a smoker
[56, 57, 58, 59]. This suggests that lung cancers are likely caused by separate biological
mechanisms in smokers versus non-smokers.
Substantial studies have identified the genes and pathways that contribute to
lung tumorigenesis in smokers (e.g., EGFR, KRAS and TP53) [56, 60], and these
discoveries have led to the development of targeted therapies (e.g., EGFR tyrosine
kinase inhibitor erlotinib; anti-VEGF antibody bevacizumab) [61]. However, most of
the studies have analyzed genetic profiles in a single assay, and the etiology of lung
tumors that arise in non-smokers remains unclear [56]. Therefore, it is worthwhile to
integrate multi-platform bioinformatic data to discover predictive biomarkers that are
associated with the smoking status of patients diagnosed with lung adenocarcinoma.
Data description
The TCGA lung adenocarcinoma data set includes samples from 225 patients, for
whom the expression intensities of 20,531 genes and 160 proteins were measured using
the respective platforms of Illumina RNA sequencing and reverse-phase protein array
(RPPA) technology. The variable of smoking status has four categories. Among the
225 patients represented in the samples, there were 49 with the status of ”current
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smoker”, 86 with ”current reformed smoker for <or=15 years”, 58 with ”current
reformed smoker for >15 years”, and 32 with ”lifelong non-smoker”.
The gene expression data were normalized using the RNA-seq by expectation-
maximization approach [62] and logarithm-transformed prior to downstream analysis.
The protein concentration data were also normalized by subtracting the median, both
column-wise and row-wise [63].
A subsample study
The six methods that I investigated aim to simultaneously analyze genetic vari-
ables to detect predictive biomarkers for a given phenotype. I am further interested
in investigating the capabilities of the methods to detect biomarkers that are likely
marginally associated with the phenotype, using individual marker tests as the refer-
ence.
I subsampled 300 genes and 100 proteins from all the genetic variables. Because
the truth is unknown in a real data study, I identified 30 genes via gene shaving [64]
or with the smallest p-values obtained from a univariate F-test; these 30 genes were
treated as the true biomarkers. The remaining 270 ”null” genes are genes that have
the largest p-values obtained from the univariate F-test. Among the 100 proteins, 10
were treated as truly important as determined by gene shaving and univariate test
results. The other 90 ”null” proteins are proteins with the largest p-values based on
the univariate F-test.
I report the results of all six methods in Table 2.2, which lists the TPR, TNR, and
FDR values. Compared to the other methods, SIFORM has superior performance in
terms of accurate biomarker detection. pCollRe has the second highest true positive
rate among the remaining methods. Lasso performs the worst in both true and false
biomarker detection, while SCAD, adaLasso, and mCCA have similar performances,
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with TPRs and TNRs that fall in between those of the other two methods. These
results are consistent with the simulation results demonstrated in the previous section.
Table 2.2: Comparison of six methods in a subsample lung study with smoking status as
outcome.
Method TPR TNR FDR
SIFORM 0.950 1.000 0.000
SCAD 0.350 0.994 0.200
Lasso 0.100 0.986 0.400
adaLasso 0.275 1.000 0.000
pCollRe 0.775 0.994 0.000
mCCA 0.500 0.986 0.000
Full data analysis
The following steps were implemented to filter out trivial genes in the RNA-
seq data. First, I removed 5% of the genes that had extremely small coe cient
of variation values, where the coe cient of variation is defined as the ratio of the
standard deviation to the absolute value of the mean of the gene expression intensities.
Second, I removed genes for which the di↵erence between the top 90% quantile and
the bottom 10% quantile was no larger than 0.8. Then, I filtered out the genes with
p-value   0.03 based on a univariate analysis of the variance F-test. This procedure
retained 3,707 genes for further analysis.
I implemented all six methods for the integrative analysis of the genomic and
proteomic data. To determine the tuning parameter values in SIFORM, I performed
a grid search over [4, 14] for  1 and [1, 10] for  2. I obtained ( 1,  2) = (5.2, 4) as the
local optimal values. SIFORM identified 17 genes that had nonzero coe cients in
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A: ATP13A4, BANK1, C20orf103, C5orf41, C7, DBF4B, FAM65C, LOC100132707,
MACROD2, PCDHAC2, RSPO2, STOM, THOC4, TLR3, TMEM173, UGT1A4,
and USP53. SIFORM also detected 13 proteins based on B: 4E-BP1, 4E-BP1 pT70,
Akt pS473, caspase-7 cleavedD198, Chk1, Chk2 pT68, EGFR pY1068, JNK2, PCNA,
PDK1 pS241, Ret pY905, stathmin, and tuberin.
I performed hierarchical clustering of the samples based on the Pearson correlation
distance and applied Ward’s linkage method to the selected genes and proteins. The
clustering heatmaps using the 17 genes and 13 proteins, respectively, are displayed in
Figure 2.3. In both panels, it can be observed that most ”non-smokers” (yellow) and
”current reformed smokers for>15 years” (orange) are clustered together. In addition,
most of the 49 ”current smokers” (blue) are mixed with some ”current reformed
smokers for <=15 years” (green). However, the data for some of the 86 recently
reformed smokers (green) behave di↵erently from the rest of the group; these samples
enlarge the overall di↵erence between the green and blue groups. The observations can
be somewhat reflected from the estimate of C = ( 0.064, 0.074, 0.015, 0.104). The
close values (c1, c2) between ”non-smokers” and ”current reformed smokers for >15
years” indicate similarity between the major genetic profiling characteristics of these
two categories of smoking status. The relatively large di↵erence between (c1, c2), c3,
and c4 manifests possible genetic profiling variations between (roughly) non-smokers,
recent smokers, and current smokers. In particular, the most di↵erent genetic profiles
are those of non-smokers compared to current smokers, which agrees with the intuitive
expectation.
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Figure 2.3.: Sample clustering based on genes and proteins selected by SIFORM
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It can also be seen from Figure 2.3 that the most identified biomarkers show clear
di↵erential expression between light smokers and heavy smokers. For instance, the
genes contained in the first 13 rows of the heatmap in the upper panel have lower
expression levels in heavy smokers but higher expression levels in light smokers, and
the bottom four genes show the opposite expression pattern. As an example, gene
UGT1A4 (the 14th gene in the upper panel of Figure 2.3) appears to be up-regulated
in the heavy smokers but down-regulated in the light smokers. Extensive evidence
shows that UGT1A4 can be induced by cigarette constituents [65, 66].
The comparisons among the six methods in terms of variable selection are sum-
marized as follows.
• SCAD, Lasso, adaLasso, pCollRe, and mCCA identified 60, 22, 33, 27, and 12
genes, respectively. SCAD detected more genes than the other methods; how-
ever, it likely yielded the largest number of false positives, as indicated by the
simulation studies. No common gene was identified across the six methods.
This implies an ongoing challenge for genetic studies of the association between
smoking and lung cancer, which is also reflected in the very limited medical
literature in this area of research. SCAD, Lasso, and mCCA, all of which are
known to produce high false positives, identified 5 genes in common. AdaLasso
and pCollRe, which are known to have appealing empirical and theoretical prop-
erties [28, 39], identified very few genes that overlap with those identified by
the other comparative methods but substantially overlap with those identified
by SIFORM. (There are 13 genes identified by both SIFORM and adaLasso; 10
genes identified by both SIFORM and pCollRe.)
• In terms of proteomic profiling, SCAD, Lasso, adaLasso, and mCCA identified
only 3, 0, 1, and 1, proteins, respectively. In contrast, the proposed method,
SIFORM, detected 13 proteins and pCollRe detected 10 proteins. SIFORM and
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pCollRe identified 9 common proteins, which makes the results of SIFORMmore
convincing due to the good empirical results of pCollRe in simulation studies.
Next, the biological relevance of the genes and proteins detected by SIFORM is
studied. Conducting pathway analysis with a web-based tool, Pathway Commons
(http://www.pathwaycommons.org/pcviz/), I discovered that 13 genes are likely to
interact with each other through functional pathways and networks. This is displayed
in Figures 2.4, where these genes are highlighted in green. The important miRNAs
associated with a common pathway are shown in red. The 8 detected proteins appear
to be in several common pathways, as highlighted in green in Figure 2.5. Several of
them are known to be associated with lung cancer.
EGFR, which was detected in the study, has been found to play a key role in lung
tumorigenesis. Approximately 10% of non-small-cell lung carcinoma (NSCLC) cases
in the U.S. and 35% in East Asia have tumor-associated EGFR mutations. EGFR
mutations are more often found in tumors from non-smokers with adenocarcinoma
histology (http://www.mycancergenome.org/content/disease/lung-cancer/egfr/)[68],
which supports the biological relevance of our finding.
Activated EGFR can regulate the activity of another detected gene, PCNA, and
trigger its important downstream signaling pathway AKT/PI3K [69]. PCNA, an
index of tumor cell proliferation, has high expression in poorly di↵erentiated lung
adenocarcinomas [70, 71]. Another detected biomarker, AKT1, is an isoform of AKT
[72]. The signal transduction pathway AKT/PI3K is involved in the regulation of cell
proliferation, survival, di↵erentiation, adhesion, motility and invasion. Aberrations of
this pathway have been implicated in lung cancer development and progression [72].
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Figure 2.4.: The network structure of genes identified by SIFORM
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Figure 2.5.: The network structure of proteins identified by SIFORM
Most of the proteins selected by SIFORM are associated with the tumorigenesis of
NSCLC through the AKT pathway, as shown by Figure 2.5. First, the activated AKT
pathway regulates tuberin (TSC2), which inhibits the mTOR nutrient signaling in-
put through the tuberous sclerosis complex. mTOR has been correlated with NSCLC
tumor progression [69, 72]. Second, the activated AKT phosphorylates CHEK1, an
integral component of the DNA damage response. The overexpression of CHEK1 is
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associated with poor tumor di↵erentiation and significantly worse patient survival in
NSCLC [73]. In addition, activated AKT induces the phosphorylation and inacti-
vation of EIF4EBP1, and the increased phosphorylation of EIF4EBP1 is found to
be associated with the progression of several types of cancer, including lung adeno-
carcinoma [74, 75, 76]. In addition to EGFR, we identified another activator of the
AKT/PI3K pathways—RET. The alteration of RET has key roles in cell growth, dif-
ferentiation, and survival, and has been associated with NSCLC [72]. In addition to
PI3K/AKT, RET signaling activates the MAPK family, including MAPK9 (JNK2)
[77]. Some studies have found that MAPK9 is frequently activated in NSCLC [78].
In summary, EGFR and its downstream PI3K/AKT pathway are among the most
important molecular therapeutic targets for NSCLC [79, 80]. Existing studies suggest
di↵erences in EFGR mutations between smokers and non-smokers, and thus implicate
the AKT/PI3K pathway and its downstream targets as playing nontrivial roles that
di↵er in patients who develop lung cancer and have a history of smoking versus those
who have never smoked. In contrast, other methods have identified only one protein,
collagen VI, which is an extracellular matrix protein. Although collagen VI has been
correlated with tumor progression, its role in NSCLC is rarely discussed [81, 82].
Cross-validation: I evaluated the predictive performance of each method used in
simulation. For simplicity, I focused on the 81 patients whose habits placed them in
the two most extreme categories related to smoking: 49 who were current smokers and
32 who were lifelong non-smokers. Specifically, I used leave-one-out cross-validation to
predict the smoking status of each patient. This procedure was repeated 81 times to
obtain the overall misclassification rate. To make a fair comparison, I focused on the
predictive performance of the top 5 biomarkers with the largest absolute coe cient
estimates. The misclassification rates of SIFORM, SCAD, Lasso, adaLasso,mCCA
and pCollRe are respectively 0.407, 0.469, 0.593, 0.556, 0.605 and 0.593. These re-
sults indicate that SIFORM has the best prediction accuracy. The overall high mis-
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classification rates across the six methods might arise from the limited sample sizes
and the recognized di culty of di↵erentiating the genetic mechanisms of lung cancer
attributable to smoking versus not smoking.
2.4.2 The association of biomarkers with survival
The 5-year survival rate of advanced lung cancer is only approximately 15%, and
conventional treatments (e.g., chemotherapy, radiotherapy) have limited impact on
improving survival for patients with advanced NSCLC. Mutations in genetic biomark-
ers result in aberrant function and uninterrupted signaling, which may lead to phar-
macological inhibition for conventional treatments. Therefore, the identification of
these biomarkers plays a key role in developing targeted cancer therapy and forming
the basis of personalized medicine [83]. The integrative analysis of multi-platform
bioinformatic data is particularly useful for precise understanding of the underlying
relationship between genetic mutations and survival in patients with lung adenocar-
cinoma.
Data description
I used the same gene expression and protein expression data from the same set
of patients that are used in Section 2.4.1. In this study, survival, instead of smoking
status, is used as the outcome. Two hundred nineteen patients with valid survival
information are divided into two groups (long-term survival (LTS) and short-term
survival (STS)) based on their survival duration. By using an extreme discordant
phenotype design [84], patients whose survivals rank in the top 25% (55 patients,
surviving >896 days) are defined as LTS, and those in the bottom 65% (29 patients,
surviving <895 days) are defined as STS. Finally, 84 patients remain for further
analysis.
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A subsample study
As in Section 2.4.1, I subsampled 300 genes and 100 proteins from all the genetic
variables. Among them, 30 genes and 10 proteins were selected via gene shaving [64]
or the univariate F-test. They were treated as true biomarkers. The remaining 270
”null” genes and 90 ”null” proteins were biomarkers that have the largest p-values
obtained from the univariate F-test.
I report the results of the implementation of all six methods in Table 2.3. Com-
pared to the other methods, SIFORM has superior performance in terms of accurate
biomarker detection. Again, pCollRe performs the second best in both true and false
biomarker detection; Lasso has the smallest TNR among the other methods; SCAD,
adaLasso, and mCCA have similar and moderate performances. These results are
consistent with the simulation results.
Table 2.3: Comparison of six methods in a subsample lung study with discretized survival
as outcome.
Method TPR TNR FDR
SIFORM 0.950 1.000 0.000
SCAD 0.325 0.992 0.000
Lasso 0.325 0.958 0.000
adaLasso 0.250 1.000 0.000
pCollRe 0.800 0.992 0.000
mCCA 0.475 0.989 0.000
Full data analysis
Using steps that are similar to those described in Section 2.4.1, I filtered out
the trivial genes in the RNA-seq data. First, I removed 10% of the genes that had
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extremely small coe cient of variation values, where the coe cient of variation is
defined as the ratio of the standard deviation to the absolute value of the mean of the
gene expression intensities. Second, I removed genes for which the di↵erence between
the top 90% quantile and the bottom 10% quantile was no larger than 0.8. Then,
I filtered out the genes with p-value   0.05 based on a univariate analysis of the
variance F-test. This procedure retained 2,529 genes for further analysis.
I implemented all six methods for the integrative analysis of the genomic and
proteomic data. To determine the tuning parameter values in SIFORM, I performed
a grid search over [1, 10] for  1 and [0, 4] for  2. The parameters ( 1,  2) = (4.7, 1.9)
are obtained as the local optimal values. SIFORM identified 12 proteins that had
nonzero coe cients in B: 4E-BP1, CD49b, Cyclin B1, ER-alpha, ER-alpha pS118,
Fibronectin, INPP4B, LCN2a, Napsin-A, PAI-1, PCNA, and TTF1. No genes were
identified as prognostic biomarkers for survival outcome in this data set.
The other methods discovered more genes (24 by SCAD, 40 by Lasso, 17 by
adaLasso, 215 by mCCA, and 29 by pCollRe) but fewer proteins (1 by SCAD, 1 by
Lasso, 1 by adaLasso, 1 by mCCA, and 4 by pCollRe) compared to SIFORM. There
is no common gene that was identified across all 5 comparative methods. There
are 8 genes that were identified by 4 methods simultaneously: CLEC4G, EPGN,
LOC392196, LOC728643, NRL, RPS6KL1, TFAP2A, and TMEM9B. However, none
of them is known to be correlated with lung cancer survival times. In terms of pro-
teomic profiling, estrogen receptor (ER)-alpha is the only protein that was discovered
by 4 methods. The prognostic values of ER expressions in lung cancer have been
extensively discussed. ER proteins, including ER-alpha, have been found to be asso-
ciated with a poorer prognosis among NSCLC patients [85, 86]. ER-alpha was also
discovered by SIFORM.
As in the previous section, I performed hierarchical clustering of the samples based
on the Pearson correlation distance and applied Ward’s linkage method to the selected
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proteins. From Figure 2.6, it can be observed that most ”STS” (yellow) and ”LTS”
(orange) are clustered together. It can also be told from this figure that most of the
identified proteins show clear di↵erential expression between ”LTS” and ”STS”.
Figure 2.6.: Sample clustering based on proteins selected by SIFORM
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I also used Kaplan-Meier curves to further investigate whether the selected pro-
teins can di↵erentiate patients with di↵erent survival durations. Specifically, I fit
logistic regression based on discretized survival and the 12 selected proteins, and
then calculated survival scores for each patient using the estimated coe cients. Each
patient was then reclassified into two subgroups (”long-term survivors” vs. ”short-
term survivors”) based on the calculated scores. Kaplan-Meier curves are plotted for
the two subgroups in Figure 2.7. It is observed that the subgroups divided by selected
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proteins have apparently di↵erent survival curves, which implies that the 12 proteins
selected by SIFORM can be good prognostic biomarkers for lung adenocarcinoma
patients.
Figure 2.7.: Kaplan-Meier curves for subgroups divided by SIFORM-selected proteins
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Kaplan-Meier Curves for Subgroups Divided by Selected Proteins
Most of the proteins identified by SIFORM are found to be biologically relevant to
lung cancer prognosis. 4E-BP1 is an eIF4E binding protein, and eIF4E is known to
be related to reduced survival in a variety of cancers, including lung adenocarcinoma.
High 4E-BP1 expression is thus found to be correlated with worse overall survival of
lung cancer patients [76, 87, 88]. Cyclin B1 plays a key role in the G2-M phase tran-
sition of the cell cycle, and elevated cyclin B1 expression levels have been found to
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indicate a poor prognosis in NSCLC [89, 90, 91]. Fibronectin, which plays an impor-
tant role in cell adhesion, migration, growth and di↵erentiation by mediating cellular
interactions with the extracellular matrix, stimulates NSCLC cell growth and survival
through activation of Akt/mTOR/p70S6K and inactivation of LKB1/AMPK signal
pathways [93, 94]. Napsin-A and TTF1 have been extensively studied as correlated
prognostic factors for survival among lung cancer patients. Patients with high expres-
sion levels of TTF-1 and Napsin-A have better survivals than those with low levels of
expression of these factors [92]. Finally, high expression levels of PAI-1 and PCNA
proteins indicate a shorter survival for patients diagnosed with lung adenocarcinoma
[95, 96].
Again, the predictive performance of each method was evaluated in this study
by leave-one-out cross-validation. The misclassification rates of SIFORM, SCAD,
Lasso, adaLasso, mCCA and pCollRe are respectively 0.322, 0.369, 0.631, 0.560, 0.417
and 0.607. SIFORM still outperformed all the other methods in terms of prediction
accuracy.
2.5 Inference on Regularized Regression Estimates
In Sections 2.2-2.4, I proposed a statistical framework, SIFORM, to integrate
multi-platform data, and developed an iterative procedure for regularized parameter
estimation. The superior performance of SIFORM in terms of biomarker detection
has been demonstrated by extensive simulations and lung cancer applications. In
this section, the assessment of statistical inference for the regularized estimates is
discussed.
It remains di cult to develop well-performing confidence intervals (CIs) and hy-
pothesis testing procedures for regularized estimates in a high-dimensional setting.
To date, only limited work in the mainstream statistical literature has addressed this
problem. Potscher et al. proposed a coverage probability theory of the confidence
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intervals for adaLasso-type estimators [97, 98], which was shown to be infeasible when
the true parameter is of similar magnitude to n 
1
2 . Lockhart and Tibshirani intro-
duced a statistic called the covariance test statistic, which is only applicable to test
the significance of the selected variables in the Lasso model [99]. Instead, Minnier et
al. proposed a perturbation method that can approximate the distribution of regu-
larized estimates for a general class of models. This perturbation method is based on
a resampling procedure [100].
I adopted this resampling-based perturbation procedure to derive CIs for biomarker
e↵ects under our framework because of its generality to di↵erent classes of penalty
functions and its robustness to a misspecified working model [100].
2.5.1 A perturbation method for inference
Recall the negative likelihood function (2.2) given in Section 2.2.2, which can be
re-expressed as
l =
nX
i=1
(
p1X
j=1
[ (x1ij   ↵1i   cl · aj)
2
2 21j
  1
2
log(2⇡ 21j)]
+
p2X
j=1
[ (x2ij   ↵2i   cl · bj)
2
2 22j
  1
2
log(2⇡ 22j)]
)
=
nX
i=1
L(✓;Di) = neL(✓), (2.13)
where D = (y,X1,X1)T and ✓ = (C,A
T ,BT ,↵1,↵2, 2T1 , 
2T
2 )
T . By using a one-
step estimator with the local linear approximation [45], minimizing the negative pe-
nalized log-likelihood function (2.3) is equivalent to minimizing
bL(✓) = eL(✓) + p1X
j=1
p
0
 1nj(|eaj|)|aj|+ p2X
j=1
p
0
 2nj(|ebj|)|bj|. (2.14)
The regularized estimator ✓ˆ for ✓0 is a minimizer of the regularized objective function
(2.14).
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The resampling-based perturbation method proposed by Minnier et al. uses the
distribution of perturbed estimators n
1
2 (✓ˆ
⇤   ✓ˆ0) to approximate the distribution of
penalized estimators n
1
2 (✓ˆ   ✓0), which lays a foundation for assessing statistical
inference for the regularized estimates [100]. The first step of this method is to
simulate a set of independent and identically distributed (i.i.d.) positive random
variables S = {Gi; i = 1, · · · , n}, where Gi has mean and variance equal to 1. Then,
by plugging Gi into the initial objective function (2.13), we obtain the perturbed
objective function
eL⇤(✓) = 1
n
nX
i=1
eL(✓;Di)Gi.
Similarly, the perturbed version of the regularized objective function is defined by
Lˆ⇤(✓) = eL⇤(✓) + p1X
j=1
p
0
 1nj(|eaj|)|aj|+ p2X
j=1
p
0
 2nj(|ebj|)|bj|, (2.15)
and the perturbed regularized estimator ✓ˆ
⇤
can be obtained in the following way:
✓ˆ
⇤
= argmin
✓
Lˆ⇤(✓). (2.16)
Let   = {j : ✓0j 6= 0} and  C = {j : ✓0j = 0}, the resampling-based perturbation
method can be justified by proving the following three statements:
(i) n
1
2 (✓ˆ
⇤
  ✓0 ) converges in distribution to n 12 (✓ˆ ✓0), N(0,A 111 B11A 111 ), where
A11 and B11 are the respective q*q submatrices corresponding to  .
(ii) The perturbed estimator has consistency in variable selection, that is, P ⇤(✓ˆ
⇤
 C =
0)! 1, where P ⇤ is the probability measure generated by both D and S.
(iii) The distribution of n
1
2 (✓ˆ
⇤
   ✓ˆ )|D approximates the unconditional distribu-
tion of n
1
2 (✓ˆ    ✓0 ).
Suppose a large number, say, M, of random samples S is generated, the perturbed
estimator ✓ˆ⇤m can be obtained for each sample m = 1, · · · ,M . Then, the above
asymptotic properties (i)(ii)(iii) allow us to approximate the theoretical distribution
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of ✓ˆ by empirical distribution
n
✓ˆ⇤m,m = 1, · · · ,M
o
. Statistical inference and the
significance test for ✓ˆ can then be carried out on the basis of ✓ˆ⇤m.
The confidence intervals of ✓ˆ can be constructed from ✓ˆ
⇤
in both parametric and
non-parametric ways. The parametric confidence interval, normal confidence interval
(CIN), is constructed on the assumption that ✓ˆ is normally distributed. Then, the
(1-↵)100% confidence interval CINj for ✓0j can be approximated by (✓ˆj  Z↵ ·  ˆ⇤j , ✓ˆj +
Z↵ ·  ˆ⇤j ), where the standard deviation  ˆ⇤j =
q
1
M
PM
m=1(✓ˆ
⇤
mj   ✓ˆj)2. To construct the
non-parametric confidence interval, quantile confidence interval (CIQ), I simply take
the 2.5th and 97.5th quantiles of ✓ˆ⇤mj as the upper and lower bounds of CI
Q
j .
I demonstrate the resampling-based perturbation method for statistical inference
through a simulation study and a lung cancer application.
Simulation study
To validate the perturbation method in finite samples, I compare the perturbed
CINs and CIQs with empirical CIs using simulated data sets in simulation scenario 1.
Recall that we have 120 samples in scenario 1, each of which has 100 genetic variables
from platform 1(X1) and 100 genetic variables from platform 2(X2). The matrices
X1 and X2 are generated by
X1 = ↵1 +CA+ "1,
X2 = ↵2 +CB + "2,
where the true coe cient vectors A1⇥100 = (5, 7, 11, 15, 18, 0, · · · , 0) and B1⇥100 =
(4, 8, 10, 14, 20, 0, · · · , 0); the four categories of the phenotype vector y is delivered by
C = (0.033, · · · , 0.033, 0.067, · · · , 0.067, 0.100, · · · , 0.100, 0.133, · · · , 0.133); the base-
lines ↵1 and ↵2 are set as 0; all ✏·j’s are simulated from distribution N(0,1).
To construct 95% empirical CIs, T (T=500) data sets are generated from the
simulation scenario 1 settings as described above, where ✏1(·j) and ✏2(·j) are simulated
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from N(0,1) with di↵erent seeds for each data set. Then, the 95% empirical CIs for
Aˆ and Bˆ are calculated from the 2.5th and 97.5th percentiles of the distribution At
and Bt, t = 1, · · · , T .
To construct perturbed CINs and CIQs, I generate M (M=500) perturbed samples
for each data set t among the T data sets. Each of the perturbed samples has a random
variable set Sm = (G1, · · · , G120) generated from an exponential distribution with
rate=1. For m=1,...,M, I plug in Sm and obtain the following closed-form solutions
for perturbed estimators ✓ˆ
⇤
m:
 ˆ2m1j =
Pn
i=1Gi(x1ij   ↵ˆ1j   cˆi · aˆj)2
n
;
 ˆ2m2j =
Pn
i=1Gi(x2ij   ↵ˆ2j   cˆi · bˆj)2
n
;
↵ˆ2m1i =
Pp1
j=1 x1ij   cˆi
Pp1
j=1 aˆj
p1
;
↵ˆ2m2i =
Pp2
j=1 x2ij   cˆi
Pp2
j=1 bˆj
p2
;
cˆml =
Pp1
j=1
aˆj
 ˆ21j
Pnl
i=nl 1+1Gi(x1ij   ↵ˆ1i) +
Pp2
j=1
bˆj
 ˆ22j
Pnl
i=nl 1+1Gi(x2ij   ↵ˆ2i)Pnl
i=nl 1+1Gi(
Pp1
j=1
aˆ2j
 ˆ21j
+
Pp2
j=1
bˆ2j
 ˆ22j
)
;
ˆamj
(k+1) =
|a(k)j |
Pn
i=1Gici(x1ij   ↵1i)
|a(k)j |
Pn
i=1Gic
2
i +  
2
1jP
0
 1
(|a(k)j |)
;
ˆbmj
(k+1)
=
|b(k)j |
Pn
i=1Gici(x2ij   ↵2i)
|b(k)j |
Pn
i=1Gic
2
i +  
2
2jP
0
 2
(|b(k)j |)
.
The perturbed 95% CINs for Aˆ
⇤
and Bˆ
⇤
are calculated from (aˆj   1.96 ·  ˆ⇤Aj, aˆj +
1.96 ·  ˆ⇤Aj) and (bˆj   1.96 ·  ˆ⇤Bj, bˆj + 1.96 ·  ˆ⇤Bj), where the standard errors  ˆ⇤Aj and
 ˆ⇤Bj come from Am and Bm. The perturbed 95% CI
Qs for Aˆ
⇤
and Bˆ
⇤
are calculated
from the 2.5th and 97.5th percentiles of the distribution Am and Bm.
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I report the coverage probabilities (CPs) and the widths of the 95% confidence
intervals CIN and CIQ for the nonzero coe cients in A⇤ and B⇤ in Table 2.4. The
widths of the 95% empirical CIs for the nonzero coe cients in A and B are also
listed for comparison.
Table 2.4: Coverage probabilities and widths of perturbed CIs (CIN and CIQ),
compared with the widths of empirical CIs( CIE) based on 500 simulation data sets
Coe↵
CIN CIQ CIE
CP( 0) CP( ˆ) Width [µ( )] CP( 0) CP( ˆ) Width [µ( )] Width
a1 0.350 1 4.865(1.133) 0.452 1 4.594(1.240) 4.598
a2 0.768 1 6.628(1.121) 0.794 1 5.560(1.031) 6.277
a3 0.962 1 4.856(1.081) 0.946 1 4.229(1.052) 4.543
a4 0.948 1 3.891(0.344) 0.948 1 3.866(0.354) 4.054
a5 0.950 1 3.896(0.352) 0.948 1 3.874(0.366) 3.908
b1 0.252 1 3.766(1.210) 0.324 1 3.342(1.322) 3.373
b2 0.852 1 6.558(1.062) 0.846 1 6.432(1.042) 6.599
b3 0.942 1 5.401(1.230) 0.942 1 4.998(1.206) 5.339
b4 0.948 1 3.932(0.375) 0.950 1 3.911(0.405) 4.353
b5 0.944 1 3.869(0.351) 0.942 1 3.842(0.356) 3.695
Overall, the widths of CIN , CIQ, and CIE are very comparable. The widths of
CIN are closer to those of CIE compared to CIQ, which tends to have a slightly
narrower confidence interval. The CP( ˆ)s of both CIN and CIQ equal 1 for all
coe cients. Both types of confidence intervals cover  ˆ with 100% probability, which
supports the expectation that the distribution of  ˆ⇤ is a good approximation of the
distribution of  ˆ. The CP( 0)s of CIN and CIQ for each coe cient are very close. As
expected, the CP( 0)s of CIN and CIQ are very close to 0.95 when the true coe cients
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are large enough, although they are apparently smaller than 0.95 for small coe cients
due to the thresholding rule of the SCAD penalty. The thresholding rule of SCAD
makes small coe cients be set at zero and moderate coe cients be shrunk towards
zero, and keeps large coe cients as they are, as the following equation shows. [32]
 ˆ =
8>>><>>>:
sgn( )(| |   )+ , when | | 6 2 
{(a  1)    sgn( )a } /(a  1) , when 2  < | | 6 a 
  , when   > a ,
where a = 3.7, as suggested by Fan et al. [32]. In this simulation scenario,  1=  2=2.8,
and are determined by BIC. Therefore, any coe cients | | 62.8 are set to 0, the
coe cients 2.8< | | 65.6 are underestimated by 2.8, the coe cients 5.6< | | 610.36
have some shrinkage, and the coe cients | | >10.36 have unbiased estimators. This
explains the low CP( 0)s of all CIs for coe cients a1 , a2, b1, and b2.
The 95% CIN and CIQ of all the 190 true zero coe cients in A and B have 100%
coverage probabilities (both CP( 0) and CP( ˆ)). The simulation results show that
the perturbed CIs have high probability of covering the true coe cient values and
comparable widths of confidence intervals compared to the empirical CIs.
I illustrate the di↵erence between the perturbed and empirical CIs by showing
CIN , CIQ, and the empirical CI of the nonzero coe cients in Figure 2.8. For demon-
stration, I only show the CIN and CIQ from one (out of the 500) data sets. It can
be told from the figure that both CIN and CIQ are very comparable to the empirical
CIs. They have similar lengths and coverage regions. Slight shifts from the empirical
CIs are observed for a5, b4, and b5, which may be due to the di↵erence between data
set 1 and the whole 500 data sets.
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Figure 2.8.: Comparison of 95% perturbed CIN s and CIQs with empirical 95% CIs for
nonzero elements in A and B (simulation)
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The comparison between Perturbed and Empirical CIs
Lung adenocarcinoma application
I used the lung adenocarcinoma data described in Section 2.4.1 to further demon-
strate the resampling-based perturbation method. Recall that we have 225 samples
in the lung cancer study, each of which has 3,707 genes, 160 proteins, and 1 four-
categorical smoking status. The association between the integrated genetic variables
and smoking status was investigated. SIFORM identified 17 genes that may be as-
sociated with smoking status: ATP13A4, BANK1, C20orf103, C5orf41, C7, DBF4B,
FAM65C, LOC100132707, MACROD2, PCDHAC2, RSPO2, STOM, THOC4, TLR3,
TMEM173, UGT1A4, and USP53. SIFORM also detected 13 proteins: 4E-BP1, 4E-
BP1 pT70, Akt pS473, caspase-7 cleavedD198, Chk1, Chk2 pT68, EGFR pY1068,
JNK2, PCNA, PDK1 pS241, Ret pY905, stathmin, and tuberin.
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I generated 500 random variable sets Sm = (G1, · · · , G225), m = 1, · · · , 500, where
Gi is simulated from the exponential distribution exp(1). I calculated 95% perturbed
CIN ’s based on the 500 perturbed samples because of the better approximation to
the empirical Cis. The perturbed CIs of the 17 identified genes and 13 identified
proteins are displayed in Figure 2.9. Only 5 biomarkers do not cover 0, including 4
proteins: 4E-BP1, 4E-BP1 pT70, Akt pS473, and Ret pY905 and 1 gene: STOM.
This may indicate that many of the identified biomarkers are false positives.
Figure 2.9.: 95% perturbed CIN s for selected biomarkers (lung cancer application)
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2.5.2 Justification for the perturbation method
This section justifies the resampling-based perturbation method. First, to ensure
the validity of the justification, we required the following regularity conditions, as in
the paper by Minnier et al. [100]:
C1: P {L(✓;D)} has a unique minimum at ✓0 and a continuous secondary deriva-
tive with a positive definite A = @2P {l(✓;D)} /@✓✓T |✓=✓0 > 0, where P is the
probability measure generated by data D.
C2: The class of functions indexed by ✓, {L(✓;D)|✓ 2 ⌦}, is Glivenko-Cantelli
[101], where ⌦ is the compact parameter space containing ✓0.
C3: There exists a quasi-derivative function U(✓;D) for L(✓;D) such that for
any positive sequence  n ! 0, we have the following denotations.
(a). P
 
U
N
2(✓0;D)
 
= B, a positive definite matrix.
(b). P {L(✓;D)  L(✓0;D)  U(✓0;D)(✓   ✓0)} = 12(✓   ✓0)TA(✓   ✓0) + o(||✓  
✓0||2), where ||✓   ✓0|| 6  n.
(c). Pn {L(✓1;D)  L(✓2;D)  U(✓2;D)(✓1   ✓2)} = 12(✓1   ✓2)TA(✓1   ✓2) +
o(||✓1 ✓2||2+n 1/2||✓1 ✓2||), almost surely, uniformly in ||✓1 ✓0|| 6  n, ||✓2 ✓0|| 6
 n, where Pn denotes the empirical measure: 8f 2 {L(✓;D)} , Pn = 1n
Pn
i=1 f(Xi).
To prove (i): n
1
2 (✓ˆ
⇤
    ✓0 ) converges in distribution to n 12 (✓ˆ  ✓0), there are the
following three steps.
(1) First, we show that e✓⇤ P! ✓0.
|eL⇤(✓)  P {L(✓;D)} |
6 |eL⇤(✓)  eL(✓)|+ |eL(✓)  P neL(✓;D)o |
= | 1
n
nX
i=1
L(✓;Di)Gi   1
n
nX
i=1
L(✓;Di)|+ | 1
n
nX
i=1
eL(✓;Di)  P neL(✓;D)o |
= |P ⇤n {L(✓;D)}  Pn {L(✓;D)} |+ |Pn
neL(✓;D)o  P neL(✓;D)o |
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By Corollary 10.14 in Kosorok et al. [101], sup
✓2⌦
|P ⇤n {L(✓;D)} Pn {L(✓;D)} |! 0 as
n!1. In addition, since {L(✓;D)|✓ 2 ⌦} is Glivenko-Cantelli, sup
✓2⌦
|Pn
neL(✓;D)o 
P
neL(✓;D)o |! 0 as n!1 [101]. Thus, |eL⇤(✓) P {L(✓;D)} | uniformly converges
to 0.
Then, by Condition C1 and Theorem 2.1 in Newey et al. [102], e✓⇤ P! ✓0.
(2) In the second step, we show that ✓ˆ
⇤ P! ✓0.
Since it is proved that e✓⇤ P! ✓0, |ea⇤j | P! |a0j| and |eb⇤j | P! |b0j|.
For the SCAD penalty, p
0
 ⇤1nj
(|ea⇤j |) =  1nI(|ea⇤j | 6  1n) + (a 1n   |ea⇤j |)+I(|ea⇤j | >
 1n)/(a 1). When a0j 6= 0, we have  1n ! 0 and |ea⇤j | P! |a0j|; thus, I(|ea⇤j | 6  1n) P! 0
and (a 1n   |ea⇤j |)+ P! 0. When a0j = 0, we have  1n ! 0 and (a 1n   |ea⇤j |)+ P! 0.
Therefore, p
0
 ⇤1nj
(|ea⇤j |) P! 0.
Since ✓ lies in a compact space,
Pp1
j=1 p
0
 ⇤1nj
(|ea⇤j |)|aj| 6 ⌧ Pp1j=1 p0 1n⇤j(|ea⇤j |) 6 ||A||Bn,
where ⌧ = max {|aj|} ,Bn = oP (1), and p0 ⇤1nj(|ea⇤j |) P! 0 for each j, by Lemma 2.9 in
Newey et al. [102], sup
✓2⌦
|Pp1j=1 p0 ⇤1nj(|ea⇤j |)|aj|| P! 0.
Similarly, sup
✓2⌦
|Pp2j=1 p0 ⇤2nj(|eb⇤j |)|bj|| P! 0.
|Lˆ⇤(✓)  P {L(✓;D)} |
= |eL⇤(✓) + p1X
j=1
p
0
 ⇤1nj
(|ea⇤j |)|aj|+ p2X
j=1
p
0
 ⇤2nj
(|eb⇤j |)|bj|  P {L(✓;D)} |
6 |eL⇤(✓)  P {L(✓;D)} |+ | p1X
j=1
p
0
 ⇤1nj
(|ea⇤j |)|aj||+ | p2X
j=1
p
0
 ⇤2nj
(|eb⇤j |)|bj||
Given that sup
✓2⌦
|Pp1j=1 p0 ⇤1nj(|ea⇤j |)|aj|| P! 0, sup✓2⌦ |Pp2j=1 p0 ⇤2nj(|eb⇤j |)|bj|| P! 0, and |eL⇤(✓) 
P {L(✓;D)} | uniformly converges to 0, |Lˆ⇤(✓)   P {L(✓;D)} | uniformly converges
to 0. Then, with an argument similar to that of step (1), we have ✓ˆ
⇤ P! ✓0.
(3) Finally, we show that ✓ˆ
⇤
converges to ✓0 with the rate of n 
1
2 : ||✓ˆ⇤   ✓0|| =
OP ⇤(n 
1
2 ). It is su cient to show that for any ✏ > 0, there exists C > 0 such that
P ⇤
8<: inf||✓ ✓0||>Cn  12 Lˆ⇤(✓) > Lˆ⇤(✓0)
9=; > 1  " (2.17)
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Consider ✓ = ✓0 + n 
1
2u. By condition C3(b), we have
Pn
n
L(✓0 + n 
1
2u)  L(✓0)  n  12U(✓0;D)Tu
o
  12n 1uTAu
||n  12u||
=
1
2(n
  12u)TAn  12u+ o(||n  12u||2)  12n 1uTAu
||n  12u||
=
o(||n  12u||2)
||n  12u|| = oP (1)
uniformly in u. By the multiplier central limit theorem (Theorem 10.1) in Kosorok
et al. [101],
P ⇤n
n
L(✓0 + n 
1
2u)G  L(✓0)G  n  12U(✓0;D)TuG
o
  12n 1uTAu
||n  12u|| = oP ⇤(1)
uniformly in u. Since P ⇤n
n
L(✓0 + n 
1
2u)G  L(✓0)G  n  12U(✓0;D)TuG
o
=
1
n
Pn
i=1
n
L(✓ + n 
1
2u)Gi   L(✓)Gi   n  12U(✓0;D)TuGi
o
= eL⇤(✓0+n  12u) eL⇤(✓0) 
n 
1
2Pn {U(✓0;D)G}u, we haveeL⇤(✓0+n  12u) eL⇤(✓0) = n  12Pn {U(✓0;D)G}u+1
2
n 1uTAu+oP ⇤(n 1||u||). (2.18)
From (2.18), it can be shown that
n
n
Lˆ⇤(✓0 + n 
1
2u)  Lˆ⇤(✓0)
o
= n
(eL⇤(✓0 + n  12u) + p1X
j=1
p
0
 ⇤1nj
(|ea⇤j |)|a0j + n  12uj|+ p2X
j=1
p
0
 ⇤2nj
(|eb⇤j |)|b0j + n  12uj|
 eL⇤(✓0)  p1X
j=1
p
0
 ⇤1nj
(|ea⇤j |)|a0j|  p2X
j=1
p
0
 ⇤2nj
(|eb⇤j |)|b0j|
)
= n
1
2 (Pn {U(✓0;D)G}  P {U(✓0;D)G})u+ n
p1X
j=1
p
0
 ⇤1nj
(|ea⇤j |)(|a0j + n  12uj|  |a0j|)
+n
p2X
j=1
p
0
 ⇤2nj
(|eb⇤j |)(|b0j + n  12uj|  |b0j|) + 12uTAu+ oP ⇤(||u||)
= Gn {U(✓0;D)G}u+ 1
2
uTAu+ n
p1X
j=1
p
0
 ⇤1nj
(|ea⇤j |)(|a0j + n  12uj|  |a0j|)
+n
p2X
j=1
p
0
 ⇤2nj
(|eb⇤j |)(|b0j + n  12uj|  |b0j|) + oP ⇤(||u||2 + ||u||), (2.19)
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where Gn = n
1
2 (Pn   P ). When u = C > 0, (2.19) apparently deviates from 0, then
(2.17) holds.
With steps (1), (2), and (3), n
1
2 (✓ˆ
⇤   ✓0) converges in distribution to n 12 (✓ˆ  ✓0).
Then, we prove (ii): P ⇤(✓ˆ
⇤
 C = 0)! 1.
It su ces to show that for any constant C and given e✓  such that ||e✓   ✓0 || =
OP ⇤(n 
1
2 )
P ⇤
8<: argmin||✓ C ||6Cn  12 Lˆ⇤[(e✓
T
 ,✓
T
 C )
T ] = 0
9=;! 1 (2.20)
Let eu  and u C denote n 12 (e✓    ✓0 ) and n 12✓ C , respectively. By (2.19), we have
n[Lˆ⇤
n
(✓T0  + n
  12 euT , n  12 euT C )To  Lˆ⇤ n(✓T0  + n  12 euT , 0T )To]
= [Gn
 
U(✓0;D)
T
 CG
 
+ euT A12]u C + 12uT CA22u C +
n
8<:X
j2 C
p
0
 ⇤1nj
(|ea⇤j |)|n  12uj|+X
j2 
p
0
 ⇤1nj
(|ea⇤j |)(|a0j + n  12 · 0|  |a0j|)
9=;
+n
8<:X
j2 C
p
0
 ⇤2nj
(|eb⇤j |)|n  12uj|+X
j2 
p
0
 ⇤2nj
(|eb⇤j |)(|b0j + n  12 · 0|  |b0j|)
9=;
+oP ⇤(||u C ||2 + ||u C ||)
= [Gn
 
U(✓0;D)
T
 CG
 
+ euT A12]u C + 12uT CA22u C + n 12 X
j2 C
p
0
 ⇤1nj
(|ea⇤j |)|uj|+
n
1
2
X
j2 C
p
0
 ⇤2nj
(|eb⇤j |)|uj|+ oP ⇤(||u C ||2 + ||u C ||)
=
X
j2 C
n
n
1
2p
0
 ⇤1nj
(|ea⇤j |)|uj|+ n 12p0 ⇤2nj(|eb⇤j |)|uj|o+Rn(u C ), (2.21)
where sup||u C || 6 CRn(u C )/(||u C ||2 + ||u C ||) = oP ⇤(1), from which we have
sup||u C || 6 oP ⇤(1) and Rn(u C ) 6 C(||u C ||2+ ||u C ||). Thus, there exists C0 > 0,
which lets P ⇤
n
Rn(u C ) 6 C0
P
j2 C |uj|
o
> 1  " for ||u C || < C.
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In addition, it is shown in Zou et al. [45] that n
1
2p
0
 ⇤1nj
(|ea⇤j |) P!1 and n 12p0 ⇤2nj(|eb⇤j |) P!
1for j 2  C . Thus, for any ✏ > 0, there exists C1 > C0 > 0 such that
P ⇤
8<:X
j2 C
[n
1
2p
0
 ⇤1nj
(|ea⇤j |)|uj|+ n 12p0 ⇤2nj(|eb⇤j |)|uj|] > C1 X
j2 C
|uj|
9=; > 1  ".
Therefore,
P ⇤
8<:X
j2 C
[n
1
2p
0
 ⇤1nj
(|ea⇤j |)|uj|+ n 12p0 ⇤2nj(|eb⇤j |)|uj|] Rn(u C ) > (C1   C0) X
j2 C
|uj|
9=; > 1 " > 0,
which implies that n[Lˆ⇤
n
(e✓T , n  12uT C )To  Lˆ⇤ n(e✓T , 0T )To] > 0, then (2.20) holds.
Finally, we prove (iii): The distribution of n
1
2 (✓ˆ
⇤
    ✓ˆ )|D approximates to the
unconditional distribution of n
1
2 (✓ˆ    ✓0 ).
Since P ⇤(✓ˆ
⇤
 C = 0)! 1, we have b✓⇤  = argminbL⇤ (✓ ) = argminbL⇤  (✓T , 0T )T .
Denote uˆ(n)  = argminbL⇤ (✓0  + n  12u ), wherebL⇤ (✓0  + n  12u )
= eL⇤ (✓0  + n  12u ) +X
j2 
p
0
 ⇤1nj
(|ea⇤j |)|a0j + n  12uj|+X
j2 
p
0
 ⇤2nj
(|eb⇤j |)|b0j + n  12uj|
= eL⇤ n(✓T0  + n  12uT ,0T )To+X
j2 
p
0
 ⇤1nj
(|ea⇤j |)|a0j + n  12uj|+X
j2 
p
0
 ⇤2nj
(|eb⇤j |)|b0j + n  12uj|
=
1
n
nX
i=1
n
L[(✓T0  + n
  12uT ,0
T )T ;Di]Gi
o
+
X
j2 
p
0
 ⇤1nj
(|ea⇤j |)|a0j + n  12uj|
+
X
j2 
p
0
 ⇤2nj
(|eb⇤j |)|b0j + n  12uj|
= Pn
n
L[(✓T0  + n
  12uT ,0
T )T ;Di]Gi
o
+
X
j2 
p
0
 ⇤1nj
(|ea⇤j |)|a0j + n  12uj|
+
X
j2 
p
0
 ⇤2nj
(|eb⇤j |)|b0j + n  12uj| (2.22)
Note that uˆ(n)  is also a minimizer of V
⇤
n (u ) ⌘ bL⇤ (✓0  + n  12u )   L⇤(✓0), since
L⇤(✓0) is constant.
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Again, from (2.19),
V n⇤(u ) = n
1
2uT Pn {U (✓0;D)G}+
1
2
uT A11u  + n
X
j2 
p
0
 ⇤1nj
(|ea⇤j |)(|a0j + n  12uj|  |a0j|)
+n
X
j2 
p
0
 ⇤2nj
(|eb⇤j |)(|b0j + n  12uj|  |b0j|) + oP ⇤(||u ||+ ||u ||2). (2.23)
When j 2  , a0j 6= 0, n 12 (|a0j+n  12uj| |a0j|) P! ujsgn(a0j). Also, it is proved by Zou
et al.[45] that n
1
2p
0
 ⇤1nj
(|ea⇤j |) P! 0 for the SCAD penalty. By Slutsky’s theorem, we have
np
0
 ⇤1nj
(|ea⇤j |)(|a0j+n 12uj| |a0j|) = oP ⇤(1). Using the same arguments, np0 ⇤2nj(|eb⇤j |)(|b0j+
n
1
2uj|  |b0j|) = oP ⇤(1) can be proved. Therefore,
V n⇤(u ) = uT Gn {U (✓0;D)G}+
1
2
uT A11u  + oP ⇤(1 + ||u ||+ ||u ||2) (2.24)
Thus, uˆ(n)  =  A 111 Gn {U (✓0;D)G}+oP ⇤(1). Since Gn {U (✓0;D)G} d! N(0,B11),
uˆ(n) 
d! N(0,A 111 B11A 111 ). That is, n 12 (✓ˆ
⇤
    ✓0 ) d! N(0,A 111 B11A 111 ).
Using similar arguments, we can obtain n
1
2 (✓ˆ    ✓0 ) =  A 111 Gn {U (✓0;D)}+
oP ⇤(1). Therefore, n
1
2 (✓ˆ
⇤
    ✓ˆ ) =  A 111 Gn {U (✓0;D)(G  1)} + oP ⇤(1). Since
 A 111 Gn {U (✓0;D)(G  1)} |D d! N(0,A 111 Bˆ11A 111 ) and Bˆ11 P! B11, n 12 (✓ˆ
⇤
   
✓ˆ )|D and n 12 (✓ˆ    ✓0 ) converge in distribution to the same limit.
2.6 Discussion
I have proposed a generalized statistical framework SIFORM to jointly model
high-throughput omic data produced by multiple platforms and to discover the as-
sociations between these genetic variables and a disease-associated phenotype. The
new method conveniently produces direct rankings of genetic variables in terms of
the strength of association with the response variable. Extensive simulation studies
demonstrated the superior performance of SIFORM in terms of biomarker detection
accuracy, regardless of inter-variable correlations, compared to the performances of
other penalized variable selection methods. Biological meaningfulness of the proposed
method is supported by two TCGA lung adenocarcinoma studies that investigated
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the association of the integrated mRNA expression and RPPA protein concentration
data with smoking status and discretized survival. In particular, most of the identi-
fied proteins either belong to known key pathways for NSCLC tumorigenesis or are
prognostic biomarkers in NSCLC. I also discovered some proteins that can potentially
predict survival for NSCLC patients or which are associated with the di↵erent ways
in which NSCLC develops in smokers versus non-smokers. The statistical significance
of the regularized estimates is also assessed by a resampling-based method.
One possibility for future research is to focus on allowing for mandatory variables
(e.g., biomarkers that are known to be correlated with the phenotype) in the proposed
system. In a di↵erent direction, information on biological pathways and networks can
be intuitively incorporated into the proposed framework to further improve the sci-
entific validity of biomarker detection. Chapter 3 discusses the methodology develop-
ment, simulations, and real applications for the incorporation of pathway information
in the analyses.
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3. Biological Pathway Information Incorporated in a
Structured Model (PSIFORM)
In this chapter, I focus on incorporating molecular pathway information into the pro-
posed statistical framework, SIFORM. The extended version of the structured model
is called pathway information incorporated in a structured model (PSIFORM). The
pathway structure among genetic variables is characterized by a graphical model, and
the network-based penalty is used to deliver the pathway information in PSIFORM.
This chapter is organized as follows. Section 3.1 provides the motivation of the
project. In section 3.2, I apply a non-convex network-based penalty to our framework
to characterize the correlation structures between the genetic variables on biological
pathways. The parameter estimation procedure is also discussed in this section. Sec-
tion 3.3 presents extensive simulation studies to compare the proposed method with
other network-based penalized regression methods. Section 3.4 contains a kidney
cancer application, through which I show that PSIFORM can jointly explore the as-
sociations of mRNA expression and protein expression with discretized survival while
utilizing existing pathway information from public databases. Section 3.5 concludes
with a summary and a discussion about future research directions.
3.1 Motivation
Genes regulate disease progression and impact phenotypes through functional
groups called pathways. The genes from the same pathway usually have similar
functions and are highly correlated. Incorporating pathway information into the inte-
grative analysis of omic data can lead to more accurate and improved interpretability
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of the results [4, 5]. Many public and commercial databases have been developed to
collect the existing biological knowledge (e.g., protein-protein interaction networks,
biological pathways). Such databases enable us to utilize the existing pathway infor-
mation [26, 27].
Numerous methods have been proposed to incorporate the biological pathway
structures into statistical analyses. Most methods use graphical models to describe
the complex structure of genetic variables between and within pathways. Specifically,
the graphical model-based methods can be classified into two major categories: the
Bayesian approach [4, 20, 24, 25] and the penalized regression approach [5, 21, 22, 23].
I focus on the penalized regression approach because it can be easily fitted into the
proposed framework.
Section 1.4 provides a brief introduction to several popular penalized regression
models for pathway incorporation. Among them, Grace, aGrace, and grouped L -
norm assume that the genes from the same pathway must have smoothed-regression
coe cients [5, 21, 22]. This assumption may be too stringent in real biological pro-
cesses. To address this problem, Kim et al. proposed a new set of network-based
penalty functions, TTLPI and LTLPI , which only assume that the genes from the
same pathway are more likely to participate (or not participate) together in the same
biological process [23]. However, this flexible method does not take multi-platform
data into consideration.
Therefore, I modify the network-based penalty of Kim et al. [23] and apply it to
SIFORM. By doing so, I model both the common structured factor across multiple
data types and the network structure within the data types in PSIFORM. The bi-
ological relevance of the results and prediction accuracy can be further improved in
PSIFORM.
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3.2 Methodology
In this section, I follow the same framework set-up as described in Section 2.2.1.
Recall that the n ⇥ 1 vector y denotes the phenotypes of n subjects, each of whom
has had continuously measured genetic variables collected from two di↵erent plat-
forms. The n⇥ p1 matrix X1 and n⇥ p2 matrix X2 respectively contain the intensity
measurements of p1 genetic variables obtained from platform 1 and the intensity mea-
surements of p2 genetic variables obtained from platform 2. The generalized statistical
framework PSIFORM is composed of
g {E(X1)} = ↵1 +CA+ "1,
g {E(X2)} = ↵2 +CB + "2. (3.1)
Similar to Section 2.2.1, for demonstration, I focus on continuously measured genetic
variables and use identity link g(µ) = µ. The n ⇥ 1 parameter vectors ↵1 and ↵2
respectively correspond to baseline sample e↵ects in two sets of genetic data. The jth
columns of the n⇥p1 residual matrix "1 and the n⇥p2 residual matrix "2 follow mean-0
normal distributions with respective variances  21j and  
2
2j. The n⇥1 parameter vector
C = {c1, ..., c1, ...., cl, ..., cl, ..., cK , ..., cK}T is structured to deliver the K-categorical
phenotype information and is employed in both equations to represent the common
intrinsic sample characteristics in the two sets of genetic data. Constraint
Pn
i=1 c
2
i = 1
is imposed for model identifiability. The length-p1 vector A and length-p2 vector B
contain the weights that the genetic variables contribute to the structured sample
characteristics shared by the two sets of genetic data.
Parameter Estimation
To identify the important genetic variables associated with the phenotype of inter-
est and incorporate pathway information at the same time, I impose a network-based
regularization on the elements of the parameter vectors A and B. First, I adopt
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SCAD, the same penalization method used in Section 2.2.2, for variable selection.
The SCAD estimators can be explicitly given by
 ˆ =
8>>><>>>:
sgn( )(| |   )+ , when | | 6 2 
{(a  1)    sgn( )a } /(a  1) , when 2  < | | 6 a 
  , when   > a ,
(3.2)
where a = 3.7, as suggested by Fan et al. [32]. Equation (3.2) shows that the SCAD
penalization method shrinks any coe cients <   to 0 [32].
Second, for incorporating pathway information, it is assumed that two neighboring
genes in the same subnetwork tend to be selected (or eliminated) simultaneously [23].
I adopt the penalty
P
i⇠j
   I( | i|!i 6= 0)  I( | j |!j 6= 0)    to model the network structure
of the genetic variables [23, 49]. However, the non-continuous indicator function I(·)
is not computationally tractable. To solve this problem, I use a truncated Lasso
penalty (TLP) as a computational surrogate of I(| | 6= 0), where TLP J⌧ (| |) =
min( | |⌧ , 1) approaches I(| | 6= 0) as ⌧ ! 0+. The parameter ⌧ determines the degree
of approximation [23, 49]. That is, any genetic variables with coe cients < ⌧ will be
eliminated from the model. To make the thresholds of SCAD and TLP in accordance
with each other, I let   and ⌧ be the same.
Thus, given tuning parameters   = ( 1, 2, 3, 4), the network-based penalty for
incorporating pathway information has the following form:
P (A,B) = P SCAD 1 (A) + P
TLP
 2, 1(A) + P
SCAD
 3 (B) + P
TLP
 4, 3(B)
=  1
p1X
j=1
 
 21   (|aj|   1)2I(|aj| <  1)
 
+  2
X
j⇠j0
    J 1( |aj|!j )  J 1( |aj0 |!j0 )
    
+  3
p2X
j=1
 
 23   (|bj|   3)2I(|bj| <  3)
 
+  4
X
j⇠j0
    J 3( |bj|!j )  J 3( |bj0 |!j0 )
     .
(3.3)
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The log-likelihood of the two sets of observed genetic data, l, takes the same form
as equation (2.2); therefore, the parameter estimates are obtained via minimizing the
following negative penalized log-likelihood,
S =  l + P SCAD 1 (A) + P TLP 2, 1(A) + P SCAD 3 (B) + P TLP 4, 3(B). (3.4)
However, minimizing the negative penalized likelihood function is computationally
challenging, because the penalty functions are non-concave and non-di↵erentiable.
The following transformations are applied to make the penalty functions di↵eren-
tiable.
First, for SCAD penalties P 1(A) and P 3(B), I adopt the local linear approxima-
tion as in Section 2.2.2 [45]. The linear approximation to P 1(|aj|) has the same form
as equation (2.4):
P 1(|aj|) ⇡ P 1(|a(k)j |) + P 0 1(|a(k)j |)(|aj|  |a(k)j |), (3.5)
where a(k)j is the value of aj estimated at step k.
Second, the non-convex TLP can be decomposed into a di↵erence of two convex
functions by DC programming [50]. Specifically, two tricks are used here: (1) The
non-convex function J⌧ (|z|) can be decomposed into the di↵erence between two convex
functions: J⌧ (|z|) = 1⌧ (|z| max(|z|  ⌧, 0)); and (2) |f1   f2| can be decomposed as
|f1   f2| = 2max(f1, f2)  (f1 + f2), where f1 and f2 are convex functions [23].
For example, after applying these two DC decompositions to P 2, 1(|aj|), I have
P 2, 1(|aj|) =
 2
 1
X
j⇠j0
[2max(uj,j0 , vj,j0)  (uj,j0 + vj,j0)], (3.6)
where uj,j0 =
|aj |
!j
+max(
|aj0 |
!j0
   1, 0) and vj,j0 = |aj0 |!j0 +max(
|aj |
!j
   1, 0).
After replacing non-di↵erentiable penalties with the above transformations, the
penalty function (3.3) can be rewritten as the di↵erence between two convex functions
P1 and P2, which can be minimized iteratively by the DC algorithm:
P (A,B) = P1   P2. (3.7)
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In this equation,
P1 =
p1X
j=1
[P 1(|a(k)j |)  P 0 1(|a(k)j |)|a(k)j |+ P 0 1(|a(k)j |)|aj|]
+
p2X
j=1
[P 3(|b(k)j |)  P 0 3(|b(k)j |)|b(k)j |+ P 0 3(|b(k)j |)|bj|]
+
 2
 1
X
j⇠j0
2max(uj,j0 , vj,j0) +
 4
 3
X
j⇠j0
2max(mj,j0 , nj,j0)
(3.8)
and
P2 =
 2
 1
X
j⇠j0
(uj,j0 + vj,j0) +
 4
 3
X
j⇠j0
(mj,j0 + nj,j0), (3.9)
where mj,j0 =
|bj |
!j
+max(
|bj0 |
!j0
  3, 0) and nj,j0 = |bj0 |!j0 +max(
|bj |
!j
  3, 0). By linearizing
P2 at a current estimate Aˆ and Bˆ and ignoring terms independent of A and B, a convex
approximation of S can be obtained at the (k + 1)th step:
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S(k+1) =
p1X
j=1
nX
i=1
[
(x1ij   ↵1i   ciaj)2
2 21j
+
1
2
log(2⇡ 21j)]
+
p2X
j=1
nX
i=1
[
(x2ij   ↵2i   cibj)2
2 22j
+
1
2
log(2⇡ 22j)]
+
p1X
j=1
[P 1(|a(k)j |)  P 0 1(|a(k)j |)|a(k)j |) + P 0 1(|a(k)j |)|aj|]
+
p2X
j=1
[P 3(|b(k)j |)  P 0 3(|b(k)j |)|b(k)j |) + P 0 3(|b(k)j |)|bj|]
+
 2
 1
X
j⇠j0
2max(uj,j0 , vj,j0) +
 4
 3
X
j⇠j0
2max(mj,j0 , nj,j0)
 
(
 2
 1
X
j⇠j0
[
ajsign(aˆj
(k))
!j
(1 + I(
|aˆj(k)|
!j
>  1))
+
aj0sign(aˆj0
(k))
!j0
(1 + I(
|aˆj0 (k)|
!j0
>  1))]
+
 4
 3
X
j⇠j0
[
bjsign(bˆj
(k)
)
!j
(1 + I(
|bˆj(k)|
!j
>  3))
+
bj0sign(bˆj0
(k)
)
!j0
(1 + I(
|bˆj0 (k)|
!j0
>  3))]
)
(3.10)
Since S(k+1) is convex, I use Matlab package CVX to minimize it in each iteration
step [103].
The closed-form solutions of all the other parameter estimates can be obtained
from equations (2.8)-(2.12); therefore, the details are omitted here. In practice, I
obtain the estimates via the iterative parameter estimation procedure as described
in algorithm 1 in Chapter 2, and the same stopping rule is adopted here. Similarly,
the optimal tuning parameters   = ( 1, 2, 3, 4) are determined by BIC by using a
four-dimensional grid search over a pre-determined space [52].
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3.3 Simulation
3.3.1 Data description
I conduct extensive simulations to assess the performance of PSIFORM and com-
pare it to those of seven regularized regression methods: Lasso, adaLasso, SCAD,
Grace, aGrace, TTLPI , and LTLPI . Lasso, adaLasso, and SCAD can be imple-
mented directly using the respective R packages ncvreg, glmnet, and parcor ; the other
network-based penalized regression methods are implemented in Matlab. The tuning
parameters of all these comparative methods are selected by a 5-fold cross-validation
procedure.
As in Section 2.3.1, I assign a phenotype variable Y categorized into four groups
and two high-dimensional genetic profiling matrices, X1 and X2, for each sample.
In the seven comparative penalized regression methods, all the genetic variables in
X1 and X2 are treated as the covariates to predict the phenotype. I use seven sim-
ulation scenarios to study the various data generation models, inter-genetic marker
dependence structures, and residual variances.
In all scenarios, I use set-ups similar to those in three published studies [5, 21, 23]
to incorporate the dependence structure among genetic variables. I simulate 120
samples in scenarios 1, 2, 3, 5, and 6, and 60 samples in scenarios 4 and 7. In
scenarios 2, 3, 5, and 6, each sample has 110 genetic variables in X1 and 110 in
X2. The 110 genetic variables consist of 10 independent subnetworks, each including
one transcription factor (TF) and 10 target genes (TGs); each TF is connected to
each of its 10 TGs with ⇢=0.8. The first two networks (that is, the first 22 genetic
variables) are correlated with the phenotype variable Y, and the TFs have larger
coe cients than the TGs. Scenario 1 is set up in a similar way. The only di↵erence
is that the genetic variables in X1 and X2 in scenario 1 are mutually independent.
Scenarios 4 and 7 consider a sparser situation. In scenarios 4 and 7, the subnetwork
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and correlation structures remain the same, but each sample has 660 genetic variables
(60 subnetworks accordingly) in X1 and 110 genetic variables in X2. The first two
subnetworks in X1 and the first subnetwork in X2 are correlated with the phenotype
variable Y.
In scenarios 1-4, the relationship between Y and genetic data X1 and X2 are
generated from model (3.1). In scenarios 5-7, the discrete phenotype Y is generated
from multinomial logistic regression models. Scenarios 1-4 model the inter-genetic
dependence structure in residual matrices "1 and "2. In scenario 1,  21j and  
2
2j are
independently simulated from N(0, 1). In scenarios 2-4, the residuals of the TFs are
distributed as N(0, 1); conditional on TF, the residuals of the TGs are distributed as
N(0.5 2TF , 0.75), and any two of the residuals are independent with each other. In
contrast, scenarios 5-7 model the data dependence structure in X1 and X2. The TF
genes inX1 andX2 are distributed as N (0, 1). Conditional on the TF expression level
XTF , the TG expression levels XTG’s are distributed as N (0.5XTF , 0.75). Similarly,
any two XTG’s are conditionally independent given XTF . Additional details for the
seven simulation scenarios are described below.
• Scenario 1: In this scenario, 120 samples are equally assigned to the four cate-
gories of the phenotype y, which gives the correspondingC = (0.033, · · · , 0.033,
0.067, · · · , 0.067, 0.100, · · · , 0.100, 0.133, · · · , 0.133). Each of the 120 samples
has 110 genetic variables in data set 1 (X1) and 110 genetic variables in data
set 2 (X2). In each data set, the first 22 genetic variables are associated with the
phenotype, and the weighted magnitudes of the nonzero coe cients in the same
subnetwork are close to each other: A1⇥110 = (20, 20p10 , · · · , 20p10 , 15,  15p10 , · · · ,  15p10 ,
0, · · · , 0) and B1⇥110 = (24, 24p10 , · · · , 24p10 , 18,  18p10 , · · · ,  18p10 , 0, · · · , 0). All the
genetic variables are mutually independent. The baselines ↵1 and ↵2 are set to
be 0, and the intensity measurements in X1 and X2 are simulated from model
(3.1).
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• Scenario 2: This scenario is the same as scenario 1, except that I assume a block-
wise compound symmetric correlation structure among the genetic variables to
mimic real biological data.
• Scenario 3: This scenario is the same as scenario 2, except that the nonzero
coe cients in the same subnetwork are randomly drawn from a uniform distri-
bution. Specifically, the generated nonzero regression coe cient vectors A and
B are: a1 = 15, a2, · · · , a6 ⇠ Unif(5, 15), a7, · · · , a11 ⇠ Unif( 15, 5), a12 =
10, a13, · · · , a17 ⇠ Unif(4, 10), a18, · · · , a22 ⇠ Unif( 10, 4) and b1 = 16, b2, · · · ,
b6 ⇠ Unif(6, 16), b7, · · · , b11 ⇠ Unif( 16, 6), b12 = 12, b17, · · · , b22 ⇠ Unif(4, 12),
b18, · · · , b22 ⇠ Unif( 12, 4). This scenario is used to determine whether PSI-
FORM can outperform the methods that have a stringent assumption on the
smoothness of the coe cients (e.g., Grace, aGrace).
• Scenario 4: A sparser setting for the data generated from the model is investi-
gated in this scenario. I consider 60 samples that are equally assigned to the
four categories of the phenotype y, with X1 and X2 respectively containing 660
and 110 genetic variables. Among the genetic variables, only the first 22 in X1
and the first 11 in X2 are the true predictors of the phenotype. The nonzero co-
e cients in coe cient vectorsA(1),A(2),A(3),B(1),B(2), and B(3) are randomly
drawn from Unif( 25, 5) [ Unif(5, 25).
• Scenario 5: In this scenario, I use a multinomial logistic regression model to
generate the phenotype y. I consider a total of 120 samples and 110 genetic
variables, where the first 22 variables are true biomarkers, in each of X1 and
X2. The genetic intensity variables in X1 and X2 follow multivariate mean-
0 normal distributions. By setting the sparse coe cient vectors A(1)1⇥110 =
(20, 20p
10
, · · · , 20p
10
, 15,  15p
10
, · · · ,  15p
10
, 0, · · · , 0),B(1)1⇥110 = (24, 24p10 , · · · , 24p10 , 18,
 18p
10
, · · · ,  18p
10
, 0, · · · , 0),A(2)1⇥110 = (18, 18p10 , · · · , 18p10 , 9,  9p10 , · · · ,  9p10 , 0, · · · , 0),
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B(2)1⇥110 = (20, 20p10 , · · · , 20p10 , 15,  15p10 , · · · ,  15p10 , 0, · · · , 0),A(3)1⇥110 = (10, 10p10 ,
· · · , 10p
10
, 3,  3p
10
, · · · ,  3p
10
, 0, · · · , 0),B(3)1⇥110 = (11, 11p10 , · · · , 11p10 , 23,  23p10 , · · ·
,  23p
10
, 0, · · · , 0), we have the logit transformed predictor ⌘il = log( P (Yi=l)P (Yi=4)) =
A(l)X1i+B(l)X2i, l = 1, 2, 3. The probability of Yi = l is pil = e⌘il/(1+
P3
k=1 e
⌘ik).
Accordingly, I sample Yi from the multinomial distributionMN(1, pi1, pi2, pi3, pi4).
One of the simulated data sets contains 71, 30, 47, and 92 samples in the four
respective categories.
• Scenario 6: This scenario is the same as scenario 5, except that the nonzero
coe cients in coe cient vectors A(1),A(2),A(3),B(1),B(2), and B(3) are ran-
domly drawn from Unif( 25, 5) [ Unif(5, 25). As an example, a simulated
data set produces 34, 39, 27, and 20 samples in the four respective phenotype
categories.
• Scenario 7: This scenario investigates the sparser settings for data generated
under a multinomial logistic regression model by simulating 60 samples, with
X1 and X2 respectively containing 660 and 110 genetic variables. Among the
genetic variables, only the first 22 in X1 and the first 11 in X2 are the true
predictors of the phenotype. Similar to scenario 5, the nonzero coe cients in
coe cient vectorsA(1),A(2),A(3),B(1),B(2), andB(3) are randomly drawn from
Unif( 25, 5) [ Unif(5, 25). A simulated data set produces 17, 15, 15, and
13 samples in the four respective phenotype categories.
3.3.2 Results
Similar to the scenarios described in Section 2.3.2, each scenario has 100 simula-
tions for stability. The mean and standard error of the true positive rate (TPR), true
negative rate (TNR), and false discovery rate (FDR) among the top genetic variables
detected that have the largest values of |A| or |B| for our method, and the largest
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absolute values of the regression coe cients for the other methods, are reported in
Table 3.1. To make a fair comparison, we focus on the top 10 biomarkers detected
by the di↵erent methods in each scenario.
Table 3.1: Comparison of TPRs, TNRs, and FDRs between PSIFORM and the other
seven methods under seven simulation scenarios
Scenario Method TPR TNR FDR
Scenario 1
PSIFORM 1.000(0.002) 0.998(0.006) 0.000(0.000)
Lasso 0.186(0.061) 0.987(0.012) 0.234(0.130)
adaLasso 0.204(0.064) 0.994(0.008) 0.165(0.085)
SCAD 0.105(0.067) 0.971(0.024) 0.390(0.250)
Grace 0.356(0.053) 0.986(0.008) 0.100(0.100)
aGrace 0.3542(0.053) 0.985(0.008) 0.100(0.100)
TTLPI 0.369(0.092) 0.999(0.002) 0.054(0.098)
LTLPI 0.435(0.155) 0.996(0.005) 0.008(0.031)
Scenario 2
PSIFORM 1.000(0.001) 0.993(0.019) 0.000(0.000)
Lasso 0.204(0.068) 0.981(0.016) 0.262(0.139)
adaLasso 0.212(0.062) 0.993(0.008) 0.170(0.089)
SCAD 0.105(0.072) 0.969(0.026) 0.396(0.269)
Grace 0.368(0.052) 0.986(0.010) 0.100(0.100)
aGrace 0.358(0.046) 0.986(0.011) 0.100(0.052)
TTLPI 0.362(0.136) 0.999(0.002) 0.042(0.103)
LTLPI 0.557(0.232) 0.994(0.009) 0.042(0.143)
Scenario 3
PSIFORM 1.000(0.001) 0.992(0.024) 0.000(0.000)
Lasso 0.273(0.061) 0.977(0.099) 0.161(0.110)
adaLasso 0.308(0.058) 0.988(0.100) 0.103(0.022)
SCAD 0.110(0.077) 0.964(0.100) 0.305(0.241)
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Grace 0.287(0.106) 0.992(0.006) 0.075(0.188)
aGrace 0.297(0.141) 0.993(0.006) 0.046(0.148)
TTLPI 0.391(0.050) 0.999(0.003) 0.018(0.041)
LTLPI 0.472(0.049) 0.997(0.007) 0.022(0.042)
Scenario 4
PSIFORM 1.000(0.001) 0.989(0.037) 0.000(0.000)
Lasso 0.200(0.053) 0.999(0.001) 0.101(0.093)
adaLasso 0.219(0.038) 1.000(0.000) 0.081(0.042)
SCAD 0.178(0.070) 0.994(0.004) 0.380(0.194)
Grace 0.266(0.091) 0.999(0.001) 0.095(0.049)
aGrace 0.289(0.149) 1.000(0.001) 0.056(0.037)
TTLPI 0.441(0.056) 1.000(0.056) 0.000(0.000)
LTLPI 0.474(0.058) 1.000(0.000) 0.000(0.000)
Scenario 5
PSIFORM 0.763(0.097) 0.964(0.034) 0.000(0.000)
Lasso 0.240(0.045) 0.945(0.025) 0.393(0.084)
adaLasso 0.178(0.072) 0.991(0.012) 0.185(0.105)
SCAD 0.147(0.055) 0.981(0.009) 0.275(0.131)
Grace 0.666(0.086) 0.997(0.003) 0.091(0.145)
aGrace 0.597(0.102) 0.997(0.005) 0.079(0.130)
TTLPI 0.729(0.103) 1.000(0.000) 0.000(0.000)
LTLPI 0.777(0.111) 1.000(0.000) 0.000(0.000)
Scenario 6
PSIFORM 0.739(0.175) 0.995(0.057) 0.085(0.227)
Lasso 0.250(0.066) 0.967(0.018) 0.267(0.129)
adaLasso 0.108(0.074) 0.988(0.020) 0.154(0.161)
SCAD 0.251(0.052) 0.974(0.011) 0.225(0.138)
Grace 0.546(0.091) 0.989(0.010) 0.181(0.300)
aGrace 0.561(0.089) 0.990(0.009) 0.181(0.300)
TTLPI 0.702(0.091) 0.981(0.020) 0.130(0.216)
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LTLPI 0.720(0.107) 0.976(0.020) 0.089(0.107)
Scenario 7
PSIFORM 0.636(0.145) 0.976(0.052) 0.085(0.027)
Lasso 0.108(0.074) 0.988(0.020) 0.154(0.161)
adaLasso 0.251(0.052) 0.974(0.011) 0.235(0.138)
SCAD 0.250(0.066) 0.967(0.018) 0.267(0.129)
Grace 0.415(0.063) 0.988(0.006) 0.206(0.107)
aGrace 0.410(0.063) 0.988(0.006) 0.206(0.185)
TTLPI 0.524(0.072) 0.980(0.022) 0.270(0.156)
LTLPI 0.545(0.099) 0.975(0.022) 0.213(0.235)
The first four scenarios correspond to the generation of data from model (3.1).
Across the first four scenarios, PSIFORM has the largest TPRs, smallest FDRs, and
comparable TNRs compared to the other methods. The simulation results demon-
strate the consistently superior performance of PSIFORM compared to all the other
methods in terms of biomarker detection accuracy when data are generated from a
model, regardless of the independence or dependence of the genetic variable structure,
di↵erent levels of dimensionality or sparsity, and various coe cient set-ups.
In scenarios 5-7, the performances of the di↵erent methods are compared when
data are generated from a multinomial logistic regression model. Di↵erent coe cient
set-ups and di↵erent dimensionalities of simulation data in the multinomial logistic
regression model are explored. Although the di↵erences between PSIFORM and the
other methods are not as large as in the first four scenarios, the advantage of using the
proposed method in terms of selecting true biomarkers is still clear: across the three
scenarios, PSIFORM always has the smallest FDRs and generally has the largest
TPRs. TTLPI and LTLPI outperform Grace and aGrace in terms of TPRs.
Across all scenarios, the network-based methods (PSIFORM/LTLPI/TTLPI/Grace
/aGrace) obviously perform better than the penalized regression methods (SCAD/Lasso/adaLasso)
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in terms of variable selection accuracy. When the true regression coe cients of neigh-
boring genes are randomly generated, PSIFORM, LTLPI , and TTLPI have higher
TPRs and TNRs than Grace and aGrace, and aGrace outperforms Grace under al-
most all criteria, as expected. Moreover, LTLPI has overall slightly larger TPRs but
lower TNRs compared to TTLPI . In sparse models (scenarios 4 and 7), PSIFORM
shows substantial advantages over the other methods in variable selection under all
criteria. The performance of PSIFORM is the most robust when a sparsity structure
exists among the variables.
In summary, PSIFORM has the best biomarker detection capability, especially
when the neighboring true predictors do not share the same coe cients or when the
model is sparse.
3.4 Kidney cancer application
In this section, I investigated the applicability of PSIFORM to the TCGA kidney
renal clear cell carcinoma (KIRC) data set, which is available through the data portal
hosted by the National Cancer Institute (http://cancergenome.nih.gov/). The objec-
tive of this study is to integrate genomic and proteomic data to discover predictive
biomarkers that are associated with the 5-year survival rates of patients diagnosed
with clear cell renal cell carcinoma (ccRCC), and incorporate pathway information
to improve the accuracy of the results.
Renal cell carcinoma (RCC) is the most common and lethal type of kidney cancer.
It is classified into four major histological cell types: clear cell (cc), papillary (10-
15%), chromophobe (5%), and collecting duct (1%). Among them, ccRCC is the
most common type of RCC, which accounts for 75-80% of total RCC cases [105].
Survival is a↵ected by the stage and grade of cancer and the clinical characteristics
of the patients. In advanced ccRCC, the 5-year survival rate is only approximately
5%-15%. Such tumors are usually resistant to chemotherapy and radiation therapy
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[106]. Therefore, it would be very valuable to identify prognostic biomarkers and
develop targeted treatments to supplement traditional therapies for ccRCC. Some
biomarkers have been well recognized for ccRCC prognosis and pathogenesis, such
as VHL, VEGFR, mTOR, HGF/c-MET, and Wnt/ -catenin signaling pathways. A
number of targeted therapies have also been developed by blocking these critical
signaling pathways [105]. The major ones include VEGF-targeted agents (sunitinib,
sorafenib and bevacizumab) and mTOR inhibitors (everolimus and temsirolimus)
[107, 108].
However, despite the advances in targeted therapies, these agents play limited roles
in the eradication of RCC because most tumors develop acquired drug resistance (e.g.,
30% of tumors show no response to sunitinib) [105]. There is a compelling need to
understand the tumorigenesis and progression mechanisms more comprehensively and
identify new prognostic biomarkers to develop novel treatments for RCC. Therefore,
it is worthwhile to incorporate biological pathway information into the integrative
analysis of mRNA and protein data to more accurately discover prognostic biomarkers
for patients with RCC.
3.4.1 Data description
The TCGA KIRC data set includes 451 patients samples, from which 20,531 genes
and 212 proteins were collected using the respective platforms of Illumina HiSeq2000
RNA sequencing and reverse-phase protein array (RPPA) technology. Among the
451 patients, 301 are censored and 150 are dead. I partitioned the patients into
two groups on the basis of their survival times. According to an extreme discordant
phenotype design [84], I took the top 20% (91 patients, surviving > 1862 days)
as long-term survivors (LTSs) and the bottom 45% (90 patients, surviving < 885
days) as short-term survivors (STSs). By doing so, 181 patient samples remained
for further analysis. The gene expression data were normalized using the RNA-
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seq by expectation-maximization approach [62] and were logarithm-transformed prior
to downstream analysis. The protein concentration data were also normalized by
subtracting the median, both column-wise and row-wise [63].
I implemented the following steps to filter out trivial genes in the RNA-seq data.
First, I removed genes with >40% missing data and used the k-nearest neighbor
algorithm with k=10 to impute genes with <40% missing data by using the R package
impute [104]. Second, I removed 25% of the genes that had extremely small coe cient
of variation values, where the coe cient of variation is defined as the ratio of the
standard deviation to the absolute value of the mean of the gene expression intensities.
Then, I removed genes for which the di↵erence between the top 80% quantile and the
bottom 20% quantile was no larger than 0.75. Finally, I filtered out the genes with
p-value >0.03 based on a univariate t-test. This procedure retained 3,361 genes for
further analysis.
I downloaded pathway information from the KEGG database [27]. After mapping
the Entrez Gene ID to the Pathway ID, among the 3,361 genes, we identified 294
genes that are associated with 32 KEGG pathways.
3.4.2 Results
I implemented all the aforementioned network-based penalized regression methods
for the integrative analysis of the genomic and proteomic data. To determine the
tuning parameter values in the proposed method, I performed a grid search for tuning
parameters  1,  2, and  3. Since pathway information for protein data is not available,
P TLP 4 is not used and there is no need to tune  4. Specifically, the gird search was
conducted over [4, 10] for  1, [0.05, 5] for  2, and [2, 6] for  3. I obtained ( 1, 2, 3)
= (6, 2.9, 4.2) as the local optimal values.
PSIFORM identified 31 genes that had nonzero coe cients in A. Among them,
15 genes belong to a metabolic pathway: ALDH3A2, DHDH, EHHADH, MGAM,
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CYP3A7, PPAP2A, GBA3, CMBL, FUT6, INPP4B, FUT3, ST6GALNAC3, AMDHD1,
FAHD1, GALNTL2; 5 genes are on the neuroactive ligand-receptor interaction path-
way: CALCRL, CHRM3, S1PR1, APLNR, EDNRB, where EDNRB also belongs to
the cGMP-PKG signaling pathway; 2 genes are on the cGMP-PKG signaling path-
way: TRPC6, PDE2A; and 9 independent genes were identified: ABCG2, C19orf77,
EMCN, NPR3, PODXL, PTPRB, RAPGEF5, SLC16A12, TMEM150C. Fourteen
proteins were also identified by PSIFORM: ACC1, AMPK pT172, AR, Cyclin B1,
GAB2, MAPK pT202 Y204, MIG-6, PDK1 pS241, Rad51, Src pY527, Tuberin, ASNS,
FASN, and p21.
I also performed hierarchical clustering of the samples based on the Pearson corre-
lation distance and applied Ward’s linkage method to the selected genes and proteins.
The clustering heatmaps based on the 31 identified genes and 15 proteins are displayed
in Figure 3.1. In both panels, it can be observed that most ”STS” (yellow) and ”LTS”
(orange) can be di↵erentiated, as the di↵erent estimates of the two group characteris-
tics in C=(-0.0747, 0.0739) reveal. It can also be seen from Figure 3.1 that the genes
in the same pathway have similar gene expression patterns. For instance, in the first
heatmap, most of the genes in the metabolic pathway, CYP3A7, MGAM, ALDH3A2,
FUT3, GBA3, EHHADH, FUT6, FAHD1, DHDH, AMDHD1, and CMBL, cluster
together at the bottom. These genes behave similarly as a functional group: they
have higher expression levels in ”LTS” but lower expression levels in ”STS”.
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Figure 3.1.: Sample clustering based on genes and proteins selected by PSIFORM
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ccRCC is fundamentally a metabolic disorder, and metabolic pathways have been
found to be mostly deregulated in ccRCC by vast cancer profiling studies [109, 110,
111]. Many of the metabolic genes identified by PSIFORM are known to be corre-
lated with ccRCC. For instance, CYP3A is confirmed to have an important role in
the detoxification of chemotherapeutic agents and is a potential predictive biomarker
for patients with metastatic renal cell carcinoma treated with sunitinib [114]; FUT3
and FUT6 genes are up-regulated in RCC [112]; and GALNTL2 is involved in the
metastatic spread of ccRCC [113, 115]. Furthermore, it is also well established that
the gene mutations in particular metabolic pathways correlate with the prognosis
in ccRCC. Some studies have revealed that many genes in metabolic pathways dis-
play reduced expression in patients with more advanced ccRCC progression, which is
consistent with our findings [111].
The neuroactive ligand-receptor interaction pathway and the cGMP-PKG signal-
ing pathway are also found to be involved in the regulation of RCC [116, 117, 118].
Specifically, some of the genes identified in these two pathways are known to be cor-
related with the progression or prognosis of RCC. For example, the overexpression of
S1PR1 is associated with increased survival times for RCC patients [119]. Similarly,
the higher expression of EDNRB indicates a significantly longer survival time among
patients with ccRCC, and has been identified as an independent prognostic marker
for ccRCC [120].
Some of the 9 independent genes are also identified as potential prognostic biomark-
ers for RCC [121, 122, 123]. For example, NPR3 has been found to be significantly
associated with the survival times of RCC patients [121]. PODXL regulates cell-to-
cell adhesion, and has been recognized as an independent predictor for survival times
among patients with RCC in multiple studies [122, 123].
In terms of protein profiling, most of the PSIFORM-selected proteins are known
critical potential markers for survival among patients with ccRCC. AMPK is a well-
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established prognostic biomarker for survival among patients with RCC. The acti-
vation of AMPK inhibits the growth and survival of renal cell carcinoma cells by
negatively regulating the mTOR signaling pathway. The down-regulation of AMPK
is associated with poor response to cancer treatments and shorter survival times
among patients with RCC [124, 125, 126]. The up-regulation of FASN, the fatty
acid synthesis gene, is correlated with worse survival times among patients with RCC
[125]. Similarly, the overexpression of cyclin B1 is associated with poor prognosis in
patients with RCC [126, 127]. MAPK cascades are key signaling pathways involved in
the regulation of cell proliferation, survival and di↵erentiation, and the suppression of
MAPK signaling pathways is known to inhibit RCC tumor growth [128]. The down-
regulation of PDK1 may be associated with aggressive disease progression in RCC
[129]. Finally, p21 is a valuable prognostic factor for ccRCC. In metastatic ccRCC,
a higher level of p21 expression is associated with a shorter survival time [130]. All
these scientific conclusions support our findings.
Kaplan-Meier curves are used to further investigate whether the 31 genes and 15
proteins selected by PSIFORM can di↵erentiate patients with di↵erent survivals. I
fitted a logistic regression model with discretized survival as the outcome and the
46 selected genetic variables as covariates. A survival score for each patient was
calculated using the estimated coe cients. Based on the calculated scores, each
patient was then reclassified into ”long-term survivors” vs. ”short-term survivors”.
Figure 3.2 shows the Kaplan-Meier curves of the two subgroups. It is observed that
the selected biomarkers clearly di↵erentiate ”long-term survivors” from ”short-term
survivors” and thus can be potential prognostic biomarkers for patients diagnosed
with ccRCC.
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Figure 3.2.: Kaplan-Meier curves for subgroups divided by PSIFORM-selected
biomarkers
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The comparisons of the other four network-based penalized regression methods
are summarized as follows.
• LTLPI , TTLPI , Grace, and aGrace identified 35, 31, 43, and 43 genes, re-
spectively. LTLPI and TTLPI yielded very similar results; Grace and aGrace
selected almost the same set of genes. Nine genes were identified by all these four
methods. They are BST1, C21orf121, DHDH, GJD4, KALRN, NPR3, PID1,
TMEM150C, and UBE2QL1. Among them, DHDH, NPR3, and TMEM150C
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were also identified by PSIFORM. BST1, KALRN, DHDH are on metabolic
pathways, but none of the remaining genes belong to any group with the same
biological function. Out of the 9 genes, NPR3 and UBE2QL1 have been found
to be associated with duration of survival among patients with RCC [131].
• In terms of proteomic profiling, LTLPI , TTLPI , Grace, and aGrace identi-
fied 11, 5, 10, and 10 proteins, respectively. Five proteins were identified by
all four methods: GAB2, Ku80, PDK1 ps241, G6PD, and GYS. GAB2 and
PDK1 ps241 were also identified by PSIFORM. PDK1 has been recognized as
being associated with renal tumor progression. The elevated expression level of
G6PD has also been observed in RCC patients [132].
None of the four methods satisfactorily captured the complex pathway structure
from the high-dimensional multi-platform data. Furthermore, only a limited number
of genes identified by the four methods belong to key pathways for tumorigenesis
or prognosis of RCC. In contrast, PSIFORM identified many gene pathways and
proteins that are known to be associated with the prognosis of patients with RCC,
which supports the capability of PSIFORM to identify biomarkers that are potentially
predictive of survival among patients with RCC.
Cross-validation: Finally, I compared the predictive performance of each method
using leave-one-out cross-validation. The prescreened KIRC data set consists of 181
patients. I fitted the PSIFORM model based on mRNA and protein expression data
from 180 patients, and then used the selected covariates to predict the discretized
survival times for the remaining patient. This procedure was repeated 181 times to
obtain the overall misclassification rate. To make a fair comparison, I focused on the
predictive performance of the top 10 biomarkers with the largest absolute coe cient
estimates. The misclassification rates of PSIFORM, LTLPI , TTLPI , Grace,and
aGrace are respectively 0.127, 0.233, 0.242, 0.291, and 0.291. PSIFORM demon-
strated the best prediction accuracy in this data set. It is noteworthy that the mis-
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classification rates in this project are much lower than those in the SIFORM project.
The incorporation of biological pathway information may contribute to the improved
predictive performance.
3.5 Summary
In Chapter 2, I propose a generalized statistical framework SIFORM to jointly
model multi-platform high-dimensional omic data and to discover the associations
between these genetic variables and a disease-associated phenotype. In this chapter,
I extend SIFORM to PSIFORM, which allows for incorporating pathway information
in multi-platform data integration to improve the accuracy and interpretability of
the results. The network structures of genes in biological pathways are character-
ized by a graphical model, and a network-based penalty is used to incorporate the
graphic structure into the proposed statistical framework. Given biological pathway
information, PSIFORM is shown to be a powerful tool in both biomarker detection
and prediction through extensive simulations and a kidney cancer application. PSI-
FORM is able to detect the biomarkers that are associated with the disease phenotype
of interest in di↵erent settings of dimensionality and coe cients.
PSIFORM also has the potential to accommodate a hierarchical order among
genetic variables across di↵erent platforms by adding additional constraints P(A,B)
to the coe cients of the variables from di↵erent platforms. For example, for any gene
i and protein j encoded by gene i, I can add the TLP penalty function P (A,B) =
p(ai, bj) = |J⌧ (|ai|)   J⌧ (|bj|)| to ensure that the genes and their encoded proteins
are selected into or eliminated from the model simultaneously. By modifying the
penalized likelihood function, PSIFORM can easily incorporate the hierarchical order
across the multi-platform omic measurements.
Currently, I use DC programming to convert a non-convex minimization problem
into an iterative convex problem, and use the Matlab package CVX to solve the convex
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problem. However, that package is not designed for high-dimensional data; hence,
the implementation speed can be severely a↵ected when the dimension of the data
increases [103]. Therefore, a possible direction of future research is to develop more
e cient numerical approaches to solve the optimization problem in a high-dimensional
space.
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